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RIASSUNTO 
 
Elevati livelli plasmatici di bilirubina non coniugata (UCB) sono responsabili dell’ittero 
neontale che è fisiologico nella maggior parte dei casi. L’iperbilirubinemia severa e prolungata 
nel tempo può causare encefalopatia da bilirubina e Kernicterus che, se non trattati, possono 
lasciare pesanti sequele neurologiche e nei casi più gravi condurre a morte. La neurotossicità da 
bilirubina è ancora una delle principali cause di malattie neurologiche nei paesi via di sviluppo ed 
è un problema riemergente nei paesi sviluppati a causa delle anticipate dimissioni dall’ospedale 
dei neonati. 
I meccanismi molecolari responsabili della neurotossicità da bilirubina non sono ancora 
completamente chiariti. Questo lavoro riporta i risultati ottenuti durante il mio progetto di 
dottorato volto a studiare il “molecular signalling” coinvolto nella neurotossicità da bilirubina. 
L’obiettivo principale è stato valutare gli effetti di concentrazioni pro-ossidanti di bilirubina sullo 
stato redox cellulare e sullo stress del reticolo endoplasmico (ER stress). Ci siamo focalizzati sulla 
pathway che coinvolge Nrf2, analizzando i geni indotti dalla bilirubina per effetto di Nrf2 e 
studiando il signalling a monte coinvolto nella sua attivazione. Parallelamente abbiamo anche 
studiato la cascata di segnali coinvolti nell’ER stress. Tutti gli esperimenti sono stati condotti nella 
linea cellulare di neuroblastoma umano SH-SY5Y, alcuni ripetuti anche nella linea di 
epatocarcinoma HepG2 e in colture primarie di astrociti dalla corteccia cerebrale di ratto. 
I nostri risultati mostrano che concentrazioni tossiche di bilirubina inducono un 40% di 
mortalità cellulare tra 1 e 4 ore di trattamento che si mantiene stabile fino alle 24 ore di trattamento. 
Le cellule trattate con UCB mostrano un incremento del livello dei ROS intracellulare dopo 1 ora 
seguito dall’accumulo nucleare dell’Nrf2 endogeno dopo 3 ore. La bilirubina aumenta l’induzione 
della trascrizione dell’ARE-GFP reporter gene associata ad una up-regolazione di diversi geni 
target di Nrf2. L’induzione dell’espressione genica può essere suddivisa in due categorie 
principali:la risposta precoce (4h-8h) e la risposta tardiva (16h-24h).La risposta precoce inizia con 
l’induzione dell’espressione di ATF3 dopo 4 ore di trattamento ed è seguita da i trasportatori di 
amminoacidi (xCT and Gly1) dopo 8h. Per la risposta tardiva abbiamo visto l’induzione 
dell’espressione genica degli enzimi coinvolti nella sintesi del glutatione. (γGCL and TNX1),nella 
risposta antiossidante e di detossificazione (HO-1, NQO1, FTH)e nell’omeostasi del NADPH 
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(ME1, and G6PD). In seguito al silenziamento specifico di Nrf2, il trattamento con bilirubina 
diminuisce l’induzione dell’mRNA solo dell’HO-1 (75%), del NQO1 (56%) e della FTH (40%) 
Inoltre l’induzione dell’HO-1 è ridotta se le cellule vengono pretrattate con l’antiossidante NAC 
(65%) e con specifici inibitori per PKC (80%), P38α (40%) and MEK1/2 (25%). 
Risulta evidente che l’induzione di ATF3 è la prima risposta generata dal trattamento con 
UCB. Di seguito abbiamo osservato un’induzione sequenziale dei marker dell’ER stress: da quelli 
coinvolti nel signaling di PERK a 4h (PERK, ATF3, ATF4, CHOP), dalla diminuzione della 
proteina della ciclina D1 dopo 1 h e dall’induzione di IRE1 (XBP1), ATF6, e BiP dopo 8h di 
trattamento. Da notare però che il silenzia mento di PERK non riduce l’induzione dell’espressione 
dell’mRNA di ATFs/CHOP, ma induce l’espressione dell’mRNA di GCN2. 
Riassumendo noi abbiamo dimostrato che la bilirubina causa mortalità cellulare, produce la 
formazione di ROS, provoca l’accumulo di Nrf2 nel nucleo e induce la risposta antiossidante 
mediata dalle sequenze ARE. La bilirubina induce l’espressione di diversi geni coinvolti nella 
risposta antiossidante, tra tutti l’HO-1 e il NQO1 sono indotti dalla bilirubina in maniera 
dipendente da Nrf2. Abbiamo anche dimostrato che lo stress ossidativo (OS) e la PKC sono i 
principali fattori coinvolti nell’attivazione di Nrf2/HO-1. I risultati ottenuti dimostrano che 
l’induzione di ATFs/CHOP e di PERK sono uno dei primi eventi associati alla tossicità da 
bilirubina. Allo stesso tempo il silenziamento di PERK non influisce sull’induzione di 
ATFs/CHOP mentre induce GCN2, suggerendo un meccanismo di compensazione tra il signalling 
di PERK e GCN2.  
Concludendo i nostri dati dimostrano che lo stress ossidativo e lo stress del reticolo 
endoplasmico sono coinvolti nella neurotossicità indotta da UCB nella linea di neuroblastoma 
umano SH-SY5Y. Le cellule sviluppano una risposta adattativa alla bilirubina inducendo OS and 
ER stress e aumentando l’espressione dei geni coinvolti nella risposta antiossidante (in parte via 
Nrf2 pathway) e nello stress del reticolo endoplasmico (UPR). 
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ABSTRACT 
 
Elevated levels of unconjugated bilirubin (UCB) are responsible for neonatal jaundice, and in 
some case, severe hyperbilirubinemia exposes babies to bilirubin encephalopathy and kernicterus 
with the risk of neurological sequela and death. Bilirubin neurotoxicity is still a major cause of 
neurological injury in the developing countries and is a re-emerged problem in the developed 
countries, due to the early hospital discharge of newborns after birth. 
The molecular mechanisms of UCB induced neurotoxicty are incompletely elucidated. Present 
thesis are reported the results obtained during my PhD course aimed to investigate the molecular 
signaling involved in UCB induced neurotoxicity .The main goal of this work was to evaluate the 
effects of the pro-oxidant concentration of UCB on cellular redox state and ER stress. We focused 
on Nrf2 pathway, analyzing the genes induced by UCB at Nrf2-dependent manner and the up-
stream signaling involved in Nrf2 pathway activation. In parallel, we also studied the ER stress 
cascade signaling. All experiments were conducted in SH-SY5Y neuroblastoma cell line, with 
some performed in HepG2 cells and primary culture of cortical astrocytes. 
Our results showed that SH-SY5Y neuroblastoma cells incubated with toxic concentration of 
UCB  suffer a 40% loss of cell viability between 1h to 4h, reaching a plateau until 24h after UCB 
treatment. Treated cells showed an increased level of intracellular ROS after 1h followed by the 
nuclear accumulation of endogenous Nrf2 after 3h. UCB enhanced the transcriptional activation 
of ARE-GFP reporter gene associated with an up-regulation of several Nrf2 target genes. 
Expression response could be divided into two main categories: early (4h-8h) and late response 
(16h-24h). As far as early genes, UCB mediates a sequential transcription starting with the ATF3 
up-regulation at 4h and followed by the induction of amino acid transporters at 8h (xCT and Gly1). 
On the contrary, for late genes, we observed an up-regulation of the enzymes involved in GSH 
synthesis (γGCL and TNX1), antioxidant/detoxification (HO-1, NQO1, FTH), and NADPH 
homeostasis (ME1, and G6PD). Specific Nrf2 siRNA against Nrf2 decreased the induction only 
of HO-1 (75%), NQO1 (56%), and FTH (40%) upon UCB exposure. HO-1 induction was reduced 
in cells pre-treated with antioxidant NAC (65%) and with specific signaling inhibitors for PKC 
(80%), P38α (40%) and MEK1/2 (25%). 
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It was evident that ATF3 up-regulation at 4h represents the earliest response to UCB exposure. 
We observed a sequential activation of UPR sensors starting with PERK signaling at 4h (up-
regulation of PERK, ATF3, ATF4, CHOP at 4h, and loss of cyclin D1 protein at 1h), followed by 
IRE1 (XBP1), ATF6, and BiP at 8h after UCB treatment. Interestingly, PERK siRNA does not 
changed the induction of ATFs/CHOP while induced GCN2 mRNA upon UCB exposure. 
In summary, we demonstrated that UCB mediates loss of cell viability, ROS generation, Nrf2 
nuclear accumulation and induction of ARE. Nrf2 pathway activation was associated with the 
induction of multiple antioxidant genes, among all, HO-1 and NQO1 are induced by UCB at Nrf2-
dependent manner. We observed that OS and PKC are the major up-stream signaling involved in 
Nrf2/HO-1 activation. Results demonstrated ATFs/CHOP induction and ER stress (initiated by 
PERK signaling) as one of the earliest event associated with UCB toxicity. However, PERK 
siRNA does not affected ATFs/CHOP induction by UCB while induced GCN2, suggesting a 
compensatory mechanism between PERK and GCN2 signaling.  
In conclusion, our data demonstrate that OS and ER stress are involved in UCB induced 
neurotoxicity in SH-SY5Y cells. The cells undergo an adaptive response against UCB induced 
OS and ER stress, through activation of multiple antioxidant genes (in part via Nrf2 pathway), 
and activation of sequential UPR sensors 
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1. INTRODUCTION 
 
Cyclic tetrapyrroles are evolutionary conserved since the life origin and occur throughout 
animal and plant kingdoms. Tetrapyrrols include vital biosynthetic products such as heme and 
chlorophyll. In animals, the end product of oxidative degradation of heme results in a yellow 
pigment named bilirubin that has a significant importance role during physiological and 
pathological conditions. This study is just a little contribution toward understanding bilirubin 
toxicity. 
 
1.1 Bilirubin, friend or foe? 
 
1.1.1 Bilirubin metabolism 
 
Bilirubin is the oxidative product of the protoporphyrin portion of the heme group present in 
hemoglobin, myoglobin, and some enzymes such as cytochromes. An adult healthy person 
produces 250-400 mg of bilirubin per day (LONDON et al., 1950). More than 80% of the bilirubin 
produced in the human body derives from heme catabolism liberated from senescent red cells in 
the spleen, about 15-20% derives from the turnover of heme-containing proteins and 3% 
destruction of immature red blood cells in the bone marrow (Ostrow et al., 1962; LONDON et al., 
1950).  
Heme degradation is performed by the reticuloendothelial enzyme heme oxygenase-1 (HO-
1), which is particularly abundant in spleen and liver Kupffer cells, the principal sites of red cell 
breakdown. This enzyme directs stereospecific cleavage of the heme ring, freeing the iron ion and 
forming a tetrapyrrolic chain with the final formation of biliverdin and carbon monoxide 
(Tenhunen et al., 1968). Following its synthesis, biliverdin is converted to bilirubin (named as 
unconjugated bilirubin (UCB)) by the cytosolic enzyme biliverdin reductase (BVR), in the 
presence of NADPH. Once released in the blood and due to its poor aqueous solubility, bilirubin 
is tightly but reversibly bound to serum albumin. Albumin binding keeps bilirubin in solution and 
transports the pigment to different organs and to the liver in particular. Albumin binds almost the 
total pigment and less than 0.1% of the UCB is unbound to albumin and named free bilirubin (Bf). 
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This Bf determine the pathophysiological properties of the pigment (Ahlfors, 2001; Weisiger et 
al., 2001). 
Despite high affinity binding to albumin, bilirubin is rapidly transferred from plasma into the 
liver. At the sinusoidal surface of the hepatocytes, bilirubin dissociates from albumin and is 
internalized. Once within the aqueous environment of the hepatocytes, bilirubin is again bound to 
a group of proteins, mainly to glutathione-S-transferases (GSTs) (Zucker et al., 1995; Boyer, 
1989). These cytosolic proteins are of importance in diminishing reflux of pigment back into the 
plasma and shuttling it to endoplasmic reticulum (ER). Inside of the ER, bilirubin is conjugated 
with either one or two molecules of glucuronic acid by the enzyme UDP-glucuronosyltransferase 
1A1 (UGT1A1) and named conjugated bilirubin (CB). These mono- and di- glucuronides display 
high polarity, which renders them water soluble and unable to diffuse across membranes, and 
allows their secretion into the bile canaliculus by the membrane transporter multidrug resistance 
protein 2 (MRP2) (Namita Roy Chowdhury et al., 2009; Xia Wang et al., 2006) . CB excreted in 
bile passes through the small intestine without significant absorption. In the colon, it is both de-
conjugated, presumably by the bacterial β-glucuronidase, and degraded by other bacterial 
enzymes to a large family of reduction-oxidation products, collectively known as urobilinoids, 
which are mostly excreted by feces (Figure 1). 
Hyperbilirubinemia is a condition in which the amount of bilirubin is elevated due to defect(s) 
that may occur at any step of bilirubin metabolism. Synthesis, uptake, conjugation, and excretion 
of bilirubin are affected by a number of acquired and inheritable conditions (Strassburg, 2010). 
The hyperbilirubinemia resulted from impaired bilirubin conjugation mechanism due to the lack 
of UGT1A1 enzyme activity is the main risky factor in neonates that may develop neurological 
disorders (see section 1.1.4). 
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Figure 1: Bilirubin metabolism. (1) Bilirubin derives from heme through that action of two enzymes: 
heme oxigenase-1 (HO-1) and biliverdin reductase (BVR). (2) Bilirubin binds to albumin in the blood and 
reaches the liver. (3) Inside endoplasmic reticulum lumen of hepatocytes, bilirubin is conjugated with 
glucuronic acid by the activity of UGT1A1 enzyme using UDP-glucuronic acid (UDPGA) as substrate. (4) 
Conjugated bilirubin is exported by MRP2 to the bile. 
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1.1.2 Bilirubin aqueous solubility and free bilirubin  
 
UCB is a nearly symmetrical tetrapyrrole, consisting of two rigid, planar dipyrrole units, 
joined by a methylene bridge at carbon 10. Depending on the pH state of the environment there is 
a significant ionization of the –COOH groups of UCB yields different forms that include di-acid, 
a mono-anion and di-anion. The low aqueous solubility of UCB di-acid is due both to its many 
hydrophobic groups and the internal hydrogen bonding of all its polar groups, precluding their 
interaction with water (Tiribelli and Ostrow, 1993). Experimental solubility near neutral pH, 
determined by chloroform-to-water partition, indicate that the maximum aqueous solubility of di-
acid form is about 70nM (Hahm et al., 1992).  
The proportion of Bf depends on albumin binding affinity constants, actually considered of 
3.1 and 2.3X106 M-1, in adults and full-term newborns, respectively. This reflect the change in 
binding affinity when albumin concentration movers from 450µM in newborn to 600µM in adult. 
UCB has a high pKa values (8.1 and 8.4) and thus at physiological pH value of plasma 7.4 the di-
acidic form is the dominant species (Ostrow et al., 1994) (Figure 2), which is able to cross any 
cell membrane by passive diffusion and determine the cellular content of UCB (Zucker et al., 
1999). 
 
 
Figure 2: (A) proportion of chemical species of UCB at different pH values derived from partition study 
representing the 80%, 16%, and 2% of di-acidic (H2B), mono-anion (HB-), and di-anion (B2-) forms 
respectively, at blood physiological concentration (pH 7.4). (B) Structures of UCB species. Figure from 
(Ostrow et al., 1994). 
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1.1.3 Bilirubin antioxidant properties 
 
It has been asked, why convert – in a step that consumes energy – biliverdin a non-toxic easily 
excretable waste product, into bilirubin, that is unexcretable, neurotoxic, and has to be further 
metabolized for dispose ?. In mammalian system, bilirubin plays a major role as a significant 
antioxidant at physiological concentrations, although we are still far from a complete 
understanding of this phenomenon (Maghzal et al., 2009). 
The antioxidant ability of UCB arises from a popular explanation of redox consuming cycling 
mechanism that act between the conversions of UCB in biliverdin . During this step, the oxidant 
species are consumed and the bilirubin regenerated via biliverdin reductase enzyme (BVR). The 
pigment may play a role similar to the glutathione cycle in cytoplasm, acting against the lipophilic 
reactive oxygen species produced from the cellular membrane, while the glutathione cycle plays 
against the cytosolic oxidative species (Baranano et al., 2002) (Figure 3).  
 
 
 
 
Figure 3: A model for the antioxidant role of bilirubin-biliverdin redox cycle. Biliverdin is formed 
from heme catabolism by heme oxygenase 1 (HO-1) and/or from direct bilirubin oxidation by reactive 
oxygen species (ROS), biliverdin is then reduced by biliverdin reductase (BV-Reductase) to bilirubin. This 
cycle is similar to glutathione redox cycle (reduced glutathione (GSH)-oxidized glutathione (GSSG)). The 
two cycles generate “celluler redox buffers” that provide a potent antioxidant environment. Figure from 
(Rigato et al., 2005). 
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Bilirubin is an antioxidant in vitro 
 
Total bilirubin concentration to about 10 µM is able to protect HeLa cells from 10000 times 
higher concentration of H2O2 (Baranano et al., 2002). Bilirubin scavenges peroxyl radicals as 
efficiently as α-tocopherol (Stocker et al., 1987b). Moreover, when binds to albumin and at 
concentration encountered in normal human plasma, UCB prevents in vitro the oxidation of 
albumin-bound fatty acids as well as of the protein itself. One mole of albumin-bound UCB can 
scavenge two moles of peroxyl radicals while being itself oxidized to its nontoxic metabolic 
precursor biliverdin (Stocker et al., 1987a; Stocker et al., 1987b; Sedlak and Snyder, 2004).  
Bilirubin is an antioxidant in vivo 
 
Support for an in vivo antioxidant capacity of bilirubin is mainly indirect. In neonates, the 
immaturity of most step in bilirubin metabolism cause a mild hyperbilirubinemia (physiological 
jaundice) characterized by a maximal serum UCB level of less than 170µM (up to 10mg/dl and in 
some cases up to 15mg/dl) (Namita Roy Chowdhury et al., 2009; Ostrow et al., 1994). The 
antioxidant properties of these modest elevations of plasma UCB are probably cell protective by 
acting as a “direct” potent antioxidant (Belanger et al., 1997; Gopinathan et al., 1994), protecting 
neonates from the free radicals produced by hemolysis (Dailly et al., 1998) and hyperoxia (Hegyi 
et al., 1994).  
Similarly, in Gilbert syndrome, the mild hyperbilirubinemia is negatively related to the risk of 
different diseases associated with oxidative stress such as atherosclerosis and cancer (Rigato et 
al., 2005; Vitek et al., 2006; Vitek et al., 2002; McCarty, 2007). Gilbert syndrome is a very 
common chronic, mild hyperbilirubinemia (total serum bilirubin around 5mg/dl (<85µM)), mainly 
due to a recessive insertional mutation in TATAA box of UGT1A1 gene. Such mutations resulting 
in a reduced level of glucoronidation UGT1A1-activity to about 30% of normal (Bosma et al., 
1995; Hirschfield and Alexander, 2006).  
UCB also possess antioxidant properties in Gunn rat animal model. Gunn rat characterized by 
long life non hemolytic unconjugated hyperbilirubinemia (at 9 days old, total serum bilirubin 
around 250µM or 15mg/dl (Gazzin et al., 2011)), due to the complete absence of UGT1A1 enzyme 
caused by a mutation on the gene (Chowdhury et al., 1993). Reduced oxidative injury to serum 
proteins and lipids was observed in the first days of life in hyperbilirubinemic neonatal Gunn rats 
exposed to hyperoxia (Dennery et al., 1995). It was also demonstrated that the hyperbilirubinemic 
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Gunn rat exhibits resistance to the pressor and the prooxidant effects of Angiotensin II. Authors 
showed that hyperbilirubinemia attenuates oxidative stress and reduces superoxide anion 
production induced by the compound (Pflueger et al., 2005). 
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1.1.4 Bilirubin is neurotoxic 
 
Neonatal jaundice occurs in most newborn due to the transient increase of plasma UCB levels 
during the first week of life (Dennery et al., 2001). This “physiological hyperbilirubinemia” acts 
as an important antioxidant molecules that protect babies from oxidative stress (Sedlak and 
Snyder, 2004; Kumar et al., 2007). However, bilirubin is a potential neurotoxic and in some cases, 
severe hyperbilirubinemia lasting for long time, leads to neuronal injury or kernicterus. Although 
bilirubin neurotoxicity is uncommon in the West (due to the well developed healthcare systems), 
it is still a major cause of neurological injury in the word. Infact it is a re-emerged disease in 
United States due to the early discharge of the newborns from hospital (Vinod K.Bhutani and Lois 
Johnson, 2005; Kaplan and Hammerman, 2004), and it has a critical importance in the developing 
countries (Gamaleldin et al., 2011; Hameed et al., 2011; Ogunlesi and Ogunfowora, 2011).  
Elevated plasma UCB level exposes babies to the risk of neurotoxicity. When the plasma level 
of UCB are excessively elevated, the unbound Bf fractions increase and cause cell toxicity or 
death. This fraction maybe elevated in association with the following conditions: 1) low blood pH 
(acidosis) (Kozuki et al., 1979). 2) reduced capacity of plasma albumin for high affinity binding 
of UCB (Kapitulnik et al., 1975). 3) use of drugs that compete with UCB for binding to plasma 
albumin (e.g., sulfonamide) (Shapiro, 1988). 4) increased bilirubin production due to 
hyperhemolysis (e.g., G6PD deficiency) (Washington et al., 1995), and 5) inherited defect of 
bilirubin conjugation mechanism (e.g., Crigler Najjar syndrome type 1) (Bosma et al., 1992; 
CRIGLER, Jr. and NAJJAR, 1952). The most vulnerable site to UCB toxicity is the central 
nervous system in which UCB produces a wide array of neurological deficits. They are named as 
“Bilirubin induced neurological dynsfunction (BIND)” when they are reversible, otherwise the 
term “kernicterus” is referred to chronic and permanent clinical sequelae of bilirubin toxicity.  
 
 
 
 
21 
 
1.1.4.1 Bilirubin induced neurological dysfunction (BIND) 
 
The classical clinical expression of BIND consists of hypotonia, lethargy, anorexia, poor 
suckling, and abnormal brainstem evoked potentials, referred to the deposition of UCB in CNS 
and are usually reversible. The preferred treatment is phototherapy which convert UCB to water 
soluble photo isomer that can be excreted in bile and urine without conjugation or parenteral 
administration of tin mesoporphyrin IX (potent inhibitor for HO-1 and thus reduce bilirubin 
synthesis). When severe neonates respond insufficiently to the above treatments, they undergo 
exchange transfusion to remove UCB from Blood (Ostrow et al., 2003; Ostrow, 1987). 
 
1.1.4.2 Kernicterus 
 
Kernicterus is a pathological term used to describe the bilirubin-induced brain injury, in 
particular the intense yellow staining of the deep nuclei of the brain (basal ganglia). Kernicterus 
occurred in about 2% of infants (Gourley, 1997) and produces a wide array of neurological 
disorders (Shapiro et al., 2006; Shapiro, 2005; Wennberg et al., 2006; Watchko, 2006). These 
include irreversible abnormalities in motor, sensory (auditory and ocular), and cognitive functions 
(Shapiro et al., 2006; Ostrow et al., 2003; Watchko, 2006; Shapiro, 2003). The most risky factor 
for kernicterus in neonates is present in Crigler Najjar syndromes. 
 
1.1.4.3 Crigler Najjar syndrome type I and II 
 
CNS I is a rare disorder, characterized by severe lifelong nonhemolytic hyperbilirubinemia 
(CRIGLER, Jr. and NAJJAR, 1952). The absence of hepatic UGT1A1 - the specific enzyme 
responsible for bilirubin conjugation (Bosma et al., 1994) - leads plasma Bf fractions extremely 
high and prolonged (serum bilirubin concentration >20 mg/dl up to 50 mg/dl (350µM-800µM) 
(Arias et al., 1969) . The majority of patients used to die of kernicterus during the first months of 
life with some exceptional patients that survived beyond maturity by applying routine 
phototherapy and plasmapheresis, but with risk of bilirubin encephalopathy (CHILDS et al., 1959; 
Berk et al., 1975; Kapitulnik et al., 1974). Liver transplantation is the only curative treatment for 
CNS I. Crigler Najjar syndrome Type II is another form of hyperbilirubinemia that is associated 
with markedly reduced activity of UGT1A1 below 30% and serum bilirubin levels range from 7 
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to 20 mg/dl (120-340µM). Patients of this form are at low risk of kernicterus (is uncommon) 
(Bosma et al., 1993; Namita Roy Chowdhury et al., 2009) and they are treated with UGT inducing 
agents such as Phenobarbital (Arias, 1962; Arias et al., 1969) that mediates transcriptional 
induction of UGT1A1 (Sugatani et al., 2005). 
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1.2 General aspects toward mechanisms of UCB induced neurotoxicity 
 
The molecular mechanisms of UCB induced neuronal injury are still incompletely elucidated 
and although free bilirubin diffuses into all brain regions and cells (Gazzin et al., 2012), it remains 
unknown why only certain types of cells, e.g. Purkinje cells (Keino et al., 1985; Conlee and 
Shapiro, 1997) are more susceptible to UCB toxicity than other cells such as astrocytes (Brito et 
al., 2008b). Even more, susceptibility to UCB toxicity is different between neuronal sub-
population (types) (Vaz et al., 2011). However, UCB-toxicity appears to be a multifaceted process 
that affects many cellular targets (Watchko, 2006). Incoming data from the literature include the 
generally untoward effects of high UCB concentrations on plasma membranes, mitochondria, ER, 
cellular bioenergetics, and intracellular calcium homeostasis (Figure 4). 
 
 
 
 
Figure 4: Mechanisms of UCB induced cell death. UCB toxicity is multifaceted and affects many cellular 
targets. 
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1.2.1 Effects of UCB on plasma membrane and mitochondria 
 
The logic primary target for UCB induced cell toxicity is at the level of plasma membranes 
which maybe related to the direct interaction of UCB with cell membrane causing oxidative 
damage, increasing membrane permeability, and decreasing lipid and protein order, as it was 
demonstrated in nerve cells (Rodrigues et al., 2002b; Brito et al., 2004). Bilirubin has a high 
affinity for membrane lipids (Brodersen, 1979). In a study of the subcellular localization of 
bilirubin within the CNS of rat brain tissue, brain bilirubin content was found to be notably high 
in the myelin fraction (Hansen et al., 2001). Several other studies suggest that membranes are the 
primary or initiating target of UCB toxicity (Silva et al., 2001a; Hansen et al., 1988; Vazquez et 
al., 1988). Despite a wealth of such data, there remains surprisingly little information regarding 
the actual nature of bilirubin–membrane complexes, nor information on why not all cell types or 
tissues bind bilirubin with equal affinity (Wennberg et al., 1979). These membrane effects, in turn, 
might contribute to the genesis of other molecular events (mitochondrial dysfunction, oxidative 
stress, ER stress, excitotoxicity, and Ca+2 homeostasis impairment). 
Early studies established that mitochondria might be a major target for UCB neurotoxicity, as 
demonstrated by impairment in mitochondrial function leading to the uncoupling of oxidative 
phosphorylation (Menken and Weinbach, 1967). Others have shown that bilirubin inhibits state 3 
respiration (Vogt and Basford, 1968). It is clear now that bilirubin can act directly on 
mitochondrial membrane to disrupt lipid polarity, fluidity, and protein order leading to increased 
membrane permeability, mitochondrial depolarization, collapse of mitochondrial transmembran 
potential, release of cytochrome-c and initiation of caspase mediated apoptosis (Rodrigues et al., 
2000; Rodrigues et al., 2002a; Rodrigues et al., 2002b; Oakes and Bend, 2005). 
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1.2.2 Excitotoxicity 
 
It is another major cause of UCB induced neuronal cell death. This mechanism is a common 
pathway among different neurodisorders (Salinska et al., 2005). Excitotoxicity is occur due to the 
overstimulation of NMDA receptors when neurotransmitter (glutamate) is not rapidly eliminated 
from extracellular matrix by the astrocytes. As a results, excessive influx of Na+, Cl-, and Ca2+ 
and water induce neuronal cell death (Mattson, 2003). Regarding the link between excitotoxicity 
and UCB, it was reported that the exposure of astrocytes to UCB decreases the uptake of glutamate 
and thus prolongs the presence of glutamate in the synaptic cleft (Silva et al., 1999; Grojean et al., 
2001). The most supportive data are those of McDonald and coworkers who showed that blockade 
of NMDA-type glutamate channels by MK-801, a selective and noncompetitive NMDA-type 
glutamate channel antagonist, reduced histological signs of bilirubin toxicity in 
hyperbilirubinemic j/j Gunn rat pups (McDonald et al., 1998). 
 
1.2.3 Effects of UCB on macromolecules 
 
Some studies showed that UCB affects macromolecules including the Inhibition of DNA 
synthesis (Schiff et al., 1985; Deganuto et al., 2010), alteration in protein functions (Hansen et al., 
1996), and changes in carbohydrate metabolism (Katoha R, 2010). However, it still unclear how 
these events contribute in UCB mediates selective neurotoxicity.  
 
1.2.4 Effects of UCB on redox state and ER 
 
Recent studies and a growing body of evidence suggest oxidative stress and ER stress as an 
important component of UCB induced neurotoxicity. The two events will be highlighted in the 
upcoming sections. 
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1.3 UCB toxicity involved oxidative stress 
 
Oxidative stress (OS) is the result of an imbalance in pro-oxidant production and cellular 
antioxidant homeostasis that leads to the generation of toxic reactive oxygen species (ROS). At 
higher concentration and long-term exposure, ROS can damage macromolecules, which leads to 
apoptotic and necrotic cell death (Kohen and Nyska, 2002; Steinbrenner and Sies, 2009). OS has 
been implicated in the progression of neurological diseases such as Alzheimer's disease, 
Parkinson's disease, Huntington’s disease, amyotrophic lateral sclerosis and many other diseases 
(Melo et al., 2011; Emerit et al., 2004; Uttara et al., 2009). Tacking in consideration the molecular 
mechanisms of UCB induced cell toxicity (described in section 1.2) it becomes more evident that 
OS is a hallmark of UCB induced cytotoxicity. Increased intracellular reactive oxygen species 
(ROS) was detected in mouse hepatoma Hepa1c1c7 cells after incubation with UCB (Seubert et 
al., 2002; Oakes and Bend, 2005). HeLa and mouse embryonic cells culture treated with UCB 
above its aqueous saturation (>70nM) showed an induced OS, promoting an increase in 
intracellular ROS which subsequently leads to the activation of redox sensor proteins APE/Ref1 
(Cesaratto et al., 2007). UCB treatment in SH-SY5Y cells induced OS and activate redox sensor 
protein DJ-1. Furthermore, the pre-treatment of SH-SY5Y cells with N-acetylcystein (NAC) an 
exogenous antioxidant showed a significant reduction in mortality upon UCB treatment 
(Deganuto et al., 2010). Further studies on primary cultures of astrocytes and neurons pointed the 
role of OS in cytotoxicity mediated by UCB (Brito et al., 2004; Brito et al., 2008a; Vaz et al., 
2011; Brito et al., 2008b; Silva et al., 2001b). Higher ROS production was observed in neurons 
compared to astrocytes while UCB toxicity was reduced by exogenous antioxidants (Vaz et al., 
2011; Silva et al., 2001b). With respect to regional differences, when primary cultures of neurons 
isolated from cerebral cortex, hippocampus, or cerebellum were exposed to UCB, hippocampal 
cells presented more oxidative damage associated with lower GSH levels compared with other 
cultures (Vaz et al., 2011). Previous published data and many others are postulated OS or 
perturbation of the cellular redox state as one of the main determinants of UCB mediated 
cytotoxicity.  
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1.4 Nrf2 is a master cellular sensor for oxidative stress 
 
 
Nuclear factor erythroid-2 related factor 2 (Nrf2) is an important transcription factor that is 
recognized as the main cellular sensor for redox state. Nrf2 belongs to the cap ‘n’ collar (CNC) 
family of transcription factors, type C-terminal basic leucine zipper (bZip) structure that facilitates 
dimerisation and DNA binding (Moi et al., 1994). Several homologous domains were identified 
when Nrf2 from different species were aligned, they are named as Neh1-6 (Nrf2-Ech-Homology). 
Functional studies using truncated forms of Nrf2 were pointed the role of each of these domains. 
Among them, Neh1 domain is the bZip that is involved in DNA binding. The Neh2 domain 
mediate binding of cytosolic repressor Keap1. The Neh4-5 contain acidic transactivation domain 
(Li and Kong, 2009a). 
 
1.4.1 Mechanisms of activation 
 
In the absence of stimuli, Nrf2 is tethered within the cytosol by inhibitory partner called Keap-
1 (Itoh et al., 1997a; Itoh et al., 1999) which interact with actin cytoskeleton (Kang et al., 2004). 
Several models were proposed for Nrf2 pathway activation and this is due to the complex structure 
of Nrf2/Keap-1. Mechanisms may involve: (A) Keap-1 modification and thus reduction in Nrf2 
ubiquitination and degradation. (B) Nrf2 phosphorylation that reduce its ubiquitination and 
degradation. (C) Direct inhibition of 26S proteosomal degradation pathway. Accepted model 
proposed that Nrf2/Keap-1 undergo a conformational change resulting in reduced Nrf2 
ubiquitination and degradation, the newly synthesized Nrf2 protein translocate to nucleus, and 
binds to ARE (Zhang, 2006; Kwak et al., 2004; Li and Kong, 2009b; Baird and Dinkova-Kostova, 
2011). 
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1.4.1.1 Activation of Nrf2 pathway by oxidative stress 
 
Oxidative and electrophilic stress is the logic and the first mediator for Nrf2 pathway 
activation. When cells are challenged by oxidative stress derived from ROS, electrophilics 
(Osburn et al., 2006; Itoh et al., 2004) or RNS (Dhakshinamoorthy and Porter, 2004; Park and 
Kim, 2005), Nrf2 is quickly translocate to nucleus. The mechanism involved thiol modification 
of redox sensitive/cysteine rich keap-1 protein (Niture et al., 2010; Li and Kong, 2009b).  
 
1.4.1.2 Activation of Nrf2 pathway by different stress response kinases 
 
Another roots involved activation of different stress response kinases by OS (Martindale and 
Holbrook, 2002; Kyaw et al., 2004), that indirectly may activate Nrf2 pathway. Several studies 
have implicated the phosphorylation of Nrf2 by different signaling protein kinases. Direct 
phosphorylation of Nrf2 on serine residue (ser40) by PKC is a very well-studied and accepted 
model (Huang et al., 2002; Bloom and Jaiswal, 2003). Other reports addressed the involvement 
of extra-cellular signal-regulated kinase (ERK) (Buckley et al., 2003; Zipper and Mulcahy, 2003; 
Papaiahgari et al., 2006), p38α MAP kinase (Zipper and Mulcahy, 2000), JNK MAP kinase (Keum 
et al., 2003), and PI3K in Nrf2 activation (Nakaso et al., 2003; Kang et al., 2002). A novel PKR-
like endoplasmic reticulum kinase (PERK) was reported to activate Nrf2 under ER stress 
conditions (Cullinan et al., 2003; Cullinan and Diehl, 2004). However, the activation of specific 
kinase(s) is dependent on the cell type and the nature of chemical inducers (Pae et al., 2008; 
Martindale and Holbrook, 2002). 
 
1.4.2 Nrf2 binds antioxidant response element (ARE) 
 
Nrf2, once activated, accumulates in the nucleus and binds specifically to the Antioxidant 
Response Element (ARE), a cis-acting enhancer with a consensus sequence defined as 5′-A/GTG 
AC/GnnnGCa/c-3′, where essential nucleotides are in capitals and the core is in bold (Nioi et al., 
2003; Jung and Kwak, 2010; Motohashi and Yamamoto, 2004). The binding of Nrf2 to the ARE 
requires hetero-dimerization with others bZip containing protein such as small Maf proteins (Itoh 
et al., 1997b). The whole cluster on ARE stimulates transcription of downstream genes, in part, 
by recruiting transcriptional co-activators (Bannister and Kouzarides, 1996) (Figure 5). 
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Figure 5: Proposed model for Nrf2 pathway activation. (A) Under basal conditions, Nrf2 is tethered by 
Keap-1 protein and ubiquitinated by Cullin-dependent E3 ubiquitin ligase complex (Cul3 complex) that 
mediates its degradation in 26S proteasome system. (B) Under induced state, OS induces a conformational 
change due to Keap-1 (thiol) modification and/or Nrf2 phosphorylation, increasing Nrf2 protein stability. 
Nrf2 moves to nucleus, binds to ARE, and induces the expression of antioxidant genes.  
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1.4.3 Nrf2 gene battery 
 
Nrf2 regulates plethora of genes called “Nrf2 gene battery” that aim to restore redox 
homeostasis (Baird and Dinkova-Kostova, 2011; Jung and Kwak, 2010; Calkins et al., 2009; Lee 
et al., 2005). Several high throughput microarray and CHIP/sequencing profiling approaches were 
proposed and many of Nrf2 target genes candidates were identified (Thimmulappa et al., 2002; 
Lee et al., 2003; Kwak et al., 2003; Li et al., 2005; Malhotra et al., 2010). These genes function 
together in the production and utilization of glutathione (see section 1.4.3.1), in the 
antioxidant/detoxification response (see section 1.4.3.2), in NADPH homeostasis (see section 
1.4.3.3) (Figure 6). Nrf2 is also involved in the transcriptional induction of ATF3, a stress-
inducible transcription factor who lies on an extensive network of stress response (see section 
1.4.3.4). 
 
 
Figure 6: Nrf2 target genes candidate. Orchestrated network of genes candidate regulated by Nrf2 
pathway. Nrf2 dependent genes identified by microarray are listed in bold italic. Figure from (Calkins et 
al., 2009). 
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1.4.3.1 Genes involved in glutathione homeostasis 
 
Glutathione (GSH) is the most abundant antioxidant non-protein thiol that work principally to 
protect cells against reactive species. GSH undergo oxidation, reduction, conjugation, and 
hydrolysis and function directly or indirectly in regulating enzyme activity, protein and DNA 
synthesis, and metabolism (Lushchak, 2012). GSH synthesis is one of the major component of the 
protection observed by Nrf2 activation (Escartin et al., 2011). Nrf2 up-regulates coordinated genes 
involved in GSH homeostasis that include: (A) Amino acid uptake transporters: xCT or SLC7A11 
(Ishii et al., 2000; Sasaki et al., 2002), and GLY1 or SLC6A9 (Lee et al., 2003) that involve in 
cysteine and Glycine uptake, respectively. (B) GSH synthesizing enzymes: The two subunits of 
the rate limiting enzyme γ-glutamylcysteine ligase catalytic (γ-GCLc) (Wild et al., 1998), and γ-
glutamylcysteine ligase modifier (γ-GCLm) (Moinova and Mulcahy, 1998). (C) GSH 
metabolizing enzymes: glutathione peroxidase (GPx) and glutathione reductase (GRx) that 
involved in the elimination of ROS through oxidation-reduction cycle (GSSG/GSH) (Lee and 
Johnson, 2004; Thimmulappa et al., 2002). (D) GSH complementary enzymes such as 
thioredoxins (Trxs) (Kim et al., 2003), a redox active proteins containing active site “dithiol motif” 
that plays a direct role in reducing oxidative species. Trxs are induced under oxidative stress and 
evidence showed that Trxs have an overlapping and highly complementary role to the GSH 
system. Trx exists in several forms with the most prevalent Trx1 (cytosolic) and Trx2 
(mitochondrial) (Watson et al., 2004). 
 
1.4.3.2 Genes involved in antioxidant/detoxification response  
 
Heme oxygenase -1 (HO-1) is the rate limiting enzyme of heme catabolism and a highly 
inducible stress response gene (Ferrandiz and Devesa, 2008). It is considered the main target of 
Nrf2 (Alam et al., 1999; Sun et al., 2002). The cytoprotection of HO-1 against OS results from its 
catalytic activity, generating three product: carbon-monoxide (CO), biliverdin-bilirubin, and 
ferrous iron (Fe+2). All of these three products have important physiologic roles against oxidative 
stress, inflammation, and apoptosis (Snyder and Baranano, 2001; Pae et al., 2008; Fang et al., 
2004; Otterbein et al., 2003; Baranano et al., 2002).  
Ferritin heavy chain (FTH) (Pietsch et al., 2003), is an antioxidant stress response gene which 
expression is enhanced on conjugation with HO-1, effectively sequester the pro-oxidative Fe+2 
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that would otherwise participate in the Fenton reaction to promote the generation of ROS (Vile 
and Tyrrell, 1993a). 
NAD(P)H:quinone oxidoreductase (NQO1) (Rushmore et al., 1991; Jaiswal, 1991) is 
multifunctional flavoprotein that mediate detoxification of reactive molecules by obligatory two-
electron reductase utilizing NADPH (NADH) as reducing cofactor. NQO1 is a powerful 
antioxidant enzyme that capable of reducing/metabolizing a very broad range of substrates in a 
single two-electron step, avoiding generation of semi-reactive species and yielding substrate for 
Phase II conjugation enzymes (Cadenas, 1995; Lind et al., 1990; Ross et al., 2000). Studies 
showed that NQO1 can catalyze the reduction of endogenous quinones such as coenzyme Q to 
ubiquinol, an effective antioxidant that protect cell membrane from oxidative damage (Landi et 
al., 1997). α-tochopherolquinone an endogenous quinone that derived from Vitamin E oxidation 
is reduced by NQO1 to α-tochopherolhydroquinone, an effective antioxidant that protect cells 
from lipid peroxidation (Siegel et al., 1997). 
Peroxiredoxins (PRDx) are antioxidant enzymes that catalyze the reduction of peroxides by 
utilizing TRX. Six isoforms of PRDx exist and some studies suggest their induction by Nrf2 
pathway such as PRDx1 (Ishii et al., 2000), PRDx2 (Li et al., 2010), and PRDx6 (Erttmann et al., 
2011). 
 
1.4.3.3 Genes involved in NADPH homeostasis 
 
NADPH an abundant antioxidants, acts as an electron donor for several oxido-reductase cycles 
and enzymes such as: GSSG-GSH cycle (Zhang et al., 2013), biliverdin-bilirubin generation, and 
NQO1 detoxification process (Calkins et al., 2009). The enzymes involved in NADPH 
homeostasis were suggested as Nrf2 target genes, such as, Malic enzyme (ME1) (Lee et al., 2003; 
Wu et al., 2011) and glucose-6-phosphate dehydrogenase (G6PD) (Mitsuishi et al., 2012; Calkins 
et al., 2009).  
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1.4.3.4 Transcription factors involved in stress response 
 
Stress response transcription factors regulate the expression of many genes that involved in 
cellular homeostasis. ATF3 is a transcription factors and a stress-inducible genes in which its 
mRNA level greatly and rapidly increase upon the exposure to stress signals (Hai and Hartman, 
2001). ATF3 lies on an extensive network of stress response that involved transcriptional 
regulation of genes involved in redox signaling, metabolic pathways, cell cycle, apoptosis, and 
signaling (Tanaka et al., 2011; Harding et al., 2003; Hunt et al., 2012). Induction of ATF3 is 
regulated at transcriptional and translational level. Recent data showed that Nrf2 is involved in 
the transcriptional induction ATF3 (Kim et al., 2010). However, another mechanisms involved 
the selective induction of ATF3 under translation inhibition (see section 1.5). 
 
1.4.4 Nrf2 activation protect cells and organs from toxic insults 
 
The coordinated induction of Nrf2 target genes represents a potential therapeutic strategy to 
protect cells and organs from oxidative injury (Lee et al., 2005) and neurotoxicity (de Vries et al., 
2008). The effects of direct antioxidants in clinical studies showing a limited beneficial effects 
due to their short half-life (instability in body), and the need for frequent use at high dosage (which 
may become toxic). Recently, an alternative and interesting approach to achieve higher and longer 
antioxidant effects is represented by indirect antioxidants. They are small molecules (such as 
sulforaphane and curcumin), that can up-regulate the expression of genes encoding antioxidant 
proteins through  Nrf2 (Jung and Kwak, 2010). Still unknown whether this strategy maybe applied 
to reduce manifestation of UCB induced neurotoxicity.  
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1.5 UCB toxicity involved ER stress 
 
1.5.1 ER stress signaling: unfolded protein response 
 
Endoplasmic Reticulum (ER) has a specialized oxidized environment that allow proper protein 
folding and processing, making the ER extremely sensitive to changes in cellular redox states 
(Malhotra and Kaufman, 2007). ER stress occurs when ER accumulate unfolded proteins and cells 
initiate a pathways known as unfolded protein response (UPR) that determine cell fate (adaptation 
or apoptosis) (Tsang et al., 2010; Ron and Walter, 2007; Lai et al., 2007; Szegezdi et al., 2006). 
The UPR consists of three main signaling initiated by three membrane associated proteins, PKR-
like ER kinase (PERK), inositol requiring enzyme 1 (IRE-1), and activating transcription factor 6 
(ATF6). These three proteins, under basal state, are bound by a chaperon called BiP (or glucose 
related protein 78, Grp78) and made inactive. Accumulation of misfolded proteins (or increase of 
oxidative stress) results in the recruitment of BiP away from UPR sensors and made them active 
(Bertolotti et al., 2000; Shen et al., 2002). Activated PERK, phosphorylates eukaryotic initiation 
factor 2 (elF2α) and leads to a general inhibition of translation and loss of cyclin D1 that mediates 
cell cycle arrest (Prostko et al., 1993; Brewer et al., 1999; Brewer and Diehl, 2000). However, 
genes carrying certain regulatory sequences (e.g., internal ribosomal entry site) in their 5´ UTR 
can bypass the translation block (Schroder and Kaufman, 2005), among them, the most studied 
are ATF3, ATF4, and CHOP (Harding et al., 2000; Jiang et al., 2004; Oyadomari and Mori, 2004). 
PERK also phosphorylates Nrf2 (Cullinan et al., 2003; Cullinan and Diehl, 2004). Activated IRE-
1, mediates selective splicing of XBP1 mRNA resulted in a stable, active transcription factor 
(Yoshida et al., 2001). ATF6 after the dissociation from BiP, translocates to Golgi apparatus where 
it is processed by peptidases (S1P and S2P). The cleaved-off cytoplasmic domain is a transcription 
factor activator of UPR (Haze et al., 1999) (Figure 7). 
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Figure 7: Signalling of Unfolded Protein Response (UPR). (A) Under basal state, ER stress transducers 
PERK, IRE1, and ATF6 are bound to chaperon BiP and made inactive. (B) Under stress state (e.g., 
oxidative stress and/or Ca2+ release …), the BiP binds to misfolded proteins and dissociate away from ER 
stress sensors. PERK phosphorylate elF2α and attenuate protein translation resulting in loss of cyclin D1 
protein and cell cycle arrest. PERK also phosphorylates Nrf2. In parallel, ATF3, ATF4, and CHOP mRNA 
are selectively induced. PERK also phosphorylate Nrf2. IRE1 activation results in the splicing of XBP1 
mRNA generating XBP1s transcription factor. Activated ATF6 translocates to Golgi where it is cealved to 
its active form transcription factor. 
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1.5.2 ER stress and UCB 
 
Few studies are reported activiation of ER stress by UCB toxicity. The first evidence that UCB 
up-regulates several genes involved in ER stress was published in 2009 by our group through a 
global transcriptome microarray approach demonstrating that UCB activates component of ER 
stress in the neuroblastoma cell line SH-SY5Y. Among others, genes induced by a treatment of 
24h with UCB include BiP and ATFs. Furthermore XBP1 unconventional splicing and 
cytoplasm/nuclear shuttling of CHOP were proved to be triggered by UCB (Calligaris et al., 
2009). Similar results were obtained by others using microarray approach in the mouse hepatoma 
Hepa 1c1c7 cell line treated with UCB (Oakes and Bend, 2010). Recently, it was shown that UCB 
in oligodendrocyte precursor cells provokes a cascade of programmed intracellular events 
triggered by an early ER stress (demonstrated by upregulation of BiP, IRE-1α, and ATF-6) that 
conduct to  cell death  and compromise myelinogenesis (Barateiro et al., 2012).  
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1.5.3 Alternative signaling to CHOP and ATF3 induction 
 
ATF3, ATF4, and CHOP are upregulated in coordination manner that takes place mainly at 
the translation level. An extensive well-studied pathway is the phosphorylate elF2α under ER 
stress that leads to upregulation of ATF3, ATF4, and CHOP (see 1.5.2). However, four distinct 
kinases are reported to phosphorylate elF2α under different cellular stress conditions in mammals 
included: heme-regulated inhibitor kinase (HRI) under heme deprivation, double-stranded RNA-
activated protein kinase (PKR) under virus infection, PERK under ER stress and general control 
non-derepressible-2 (GCN2) under amino acid deprivation (AAD) (Donnelly et al., 2013). Studies 
showed that PERK and GCN2 contribute in the translation inhibition via elF2α phosphorylation 
(Hamanaka et al., 2005) and to the induction of ATFs and CHOP (Wang et al., 2013; Jiang et al., 
2004; Cai and Brooks, 2011).  
Another interesting pathway involved in regulation of protein translation and linked to AAD 
and stress conditions is named mTOR signaling (mammalian target of rapamycin). Under normal 
conditions an activated mTOR is involved in protein synthesis via hyperphosphorylation of eIF4E 
binding protein (4E-BP) keeping it away to interact with eukaryotic translation initiation factor 
4E (eIF4E). When mTOR is inactivated (e.g., by AAD), the 4E-BP become hypophosphorylated, 
promoting their interaction with eIF4E. This interaction sequesters eIF4E and blocks translation. 
Under these conditions certain mRNAs include ATF4 and CHOP continue to be translated 
(Entingh et al., 2001; Bunpo et al., 2009; Thomas et al., 2008; Koritzinsky et al., 2006)  
38 
 
 
Figure 8: Proposed model of translation inhibition and CHOP/ATFs induction by stress signals. 
Various stress evoke activation of distinct signaling pathways resulting in the reduction of protein 
synthesis. On one side activation of eIF2α kinases by PERK and/or HRI and/or PKR and/or GCN2 results 
in eIF2α phosphorylation. On another side stress conditions inactivate the mammalian target of rapamycin 
(mTOR) resulting in a hypophosphorylation of 4E-BP, which binds to eIF4E. Under both conditions 
translation block occurred and certain mRNAs, as ATF4 and CHOP, continue to be translated. Figure 
modified from (Holcik and Pestova, 2007). 
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2. AIM AND SCOPE OF THE THESIS 
 
The main goals of the present work is to further contribute for a better understanding of the 
molecular mechanisms of UCB induced neurotoxicity and to identify potential possible target to 
reduce UCB neurotoxicity using in vitro models. All experiments were performed in the 
neuroblastoma SH-SY5Y cell line, with some performed in HepG2 cells and primary culture of 
rat cortical astrocytes. The thesis specific aim is to evaluate the effects of the pro-oxidant 
concentration of UCB on cellular redox state and ER stress through four different steps: 
1) To evaluate the effects of UCB on cellular redox state, with focus on antioxidant response 
activation through Nrf2 pathway. 
 
2) To study the down-stream genetic changes upon UCB exposure and to clarify early and 
late response.   
 
3) To identify the genes up-regulated by UCB at Nrf2 dependent manner and to evaluate the 
up-stream signaling involved in Nrf2 pathway activation. 
 
4) To study the effects of UCB on ER stress, with focus on the sequential expression of UPR 
markers  
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3. MATERIALS AND METHODS 
 
3.1 Cells culture 
 
3.1.1 SH-SY5Y cells 
 
Human neuroblastoma cell line SH-SY5Y were maintained in Eagle’s Minimum Essential 
Medium (EMEM)/ Ham’s F-12 Nutrient Mixture at 1:1 ratio supplemented with 15% (v/v) fetal 
bovin serum (FBS), 1% (v/v) penicillin streptomycin solution (100 U/mL penicillin, 100 mg/mL 
streptomycin), 2 mM L-GlutaMAXTM and 1% (v/v) non-essential amino acids (Sigma Aldrich, 
Milan, Italy). Cells were grown at 37°C in a humidified atmosphere of 5% CO2. The cells were 
fed every 2 days and sub-cultured once they reached 80-90% confluence.  
 
3.1.2 HepG2 cells 
 
Human hepatocellular carcinoma HepG2 were maintained in Dulbecco’s Eagle’s high glucose 
medium (DMEM) supplemented with 10% (v/v) FBS and 1% (v/v) penicillin streptomycin 
solution and 2mM L-glutamine (Sigma Aldrich). Cells were grown at 37°C in a humidified 
atmosphere of 5% CO2 and were sub-cultured once they reached 80-90% confluence.  
 
3.1.3 Primary culture of rat cortical astrocytes 
 
Wistar HanTM Rats (P2) of both sexes were obtained from the animal facility of the Department 
of Life sciences of Trieste University (Italy). Animal care and procedures were conducted 
according to the guidelines approved by the Italian law (decree 116-92) and by the European 
Communities Council Directive 86-609-ECC.  
P2 wistar rats were used for primary culture of astrocytes as described previously by Booher  
et al (Booher and Sensenbrenner, 1972) with some modification. Briefly, animals were sacrificed 
by decapitation; their brains were rapidly excised and placed in DMEM Low glucose (Gibco 
31885-049) culture medium. Under the stereomicroscope, the cortex (Cx) were immediately 
dissected, cleaned from meninges and choroid plexus. The different parts were collected in 
DMEM Low glucose supplemented with 1% of penicillin/streptomycin and cut in small pieces. 
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Cells were dissociated by forcing the tissue through a 70 µm nylon cell strainer with 3 mL of 
culture medium DMEM supplemented by 10% of heat-inactivated FBS, 50ug/mL gentamycin, 
and 1% penicillin/streptomycin. The cell suspension was further dissociated by a 5 ml pipette to 
avoid cells aggregates. The latter suspension was diluted ¼ and cells were seeded at 1.2 105 
cells/cm2 in 6 multiwell plates. Cx astrocytes were incubated in the culture medium and 
maintained in the incubator at 37°C in a humidified atmosphere of 5% CO2.  
 
3.2 Bilirubin preparation and treatment (General protocol) 
 
  
Unconjugated bilirubin (UCB) (Sigma Chemical Co, St. Louis MO), was purified as described 
by Ostrow & Murkerjee (Ostrow and Mukerjee, 2007). An aliquot of purified UCB was dissolved 
in DMSO (0.33 μL of DMSO per μg of UCB) obtaining a final concentration of 5 mM and then 
added to the culture with FBS. In the different UCB solutions, the concentration of free bilirubin 
(Bf), the portion of unconjugated bilirubin not bound to albumin and responsible of bilirubin 
neurotoxic effect, was measured by (Calligaris et al., 2006). Cells exposed to the same 
concentration of DMSO that carry bilirubin in growth medium were used as controls.  
 
3.3 Cells viability determined by MTT assay 
 
 
SH-SY5Y cells were seeded at 80000 cell/cm2 in 24 multiwall plate and then treated with 140 
nM Bf for 1h, 4h, 8h, 16h, and 24h. After the indicated time, cells viability were determined by 
3(4,5-dimethylthiazolyl-2)-2,5 diphenyl tetrazolium (MTT) assay (Twentyman and Luscombe, 
1987). The stock of 3(4,5-dimethyltiazolyl-2)-2,5 diphenyl tetrazolium (MTT) (Signal Aldrich) 
was dissolved in PBS pH 7.4 at 5 mg/mL and finally diluted in growth medium to a final 
concentration of 0.5 mg/mL. The cells were incubated with the MTT solution for at least 1 hours 
at 37 °C. After incubation, the medium was discarded, the  MTT formazan crystals were dissolved 
in 0.4 mL of DMSO, and the sample gentle shook for 15 min. Absorbance values at 562 nm were 
determined in a LD 400C Luminescence Detector (Beckman Coulter, Milan, Italy). Results were 
expressed as percentage of control cells, exposed to 0.6% DMSO, which was considered as 100% 
viability.   
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3.4 ROS determination by fluorescence dye (H2DCFDA) 
 
 
The Intracellular ROS accumulation after UCB treatment was determined using the 2’7’-
dichlorofluorescein diacetate (H2DCF-DA) compound (Molecular Probes, Carlsbad, CA, USA), 
which is a non-polar compound converted into a non-fluorescent polar derivative (H2DCF) by 
cellular esterases after incorporation into cells. H2DCF is membrane-impermeable and is oxidized 
rapidly to the highly fluorescent 20, 70-dichlorofluorescein (DCF) in the presence of intracellular 
ROS. 60.000 of SH-SY5Y cells/cm2 were seeded in six multi-well plates and growth up to 70% 
of confluence. Cells were pre-treated for 15 min with 10 µM H2DCF-DA diluted in serum free 
medium added with 25 mM Hepes, and finally exposed to a 140 nM Bf for 1h. Cells treated with 
0.6% DMSO or 0.2 mM H2O2 were used as negative and positive controls, respectively. At the 
end of the treatment, cells were washed with PBS, detached by trypsinization and re-suspended in 
PBS for FACS analysis. The intensity of fluorescence was measured with a BD FACS Callibur 
(Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed with CellQuest Pro software. 
 
3.5 Total protein extraction and Western blot (General protocol) 
 
SH-SY5Y cells were seeded and once reached 80% confluence, they treated with 140 nM Bf 
or 0.6% DMSO for 1h, 4h, 8h, 16h, and 24h. After indicated time, total protein extracts were 
obtained by lysing the cells in ice-cold Cell Lysis Buffer (#9803, Cell Signaling Technology, Inc 
-Beverly, Massachusetts, USA) for 10 min, on ice, and using scrapper. The lysate was centrifuged 
at 14.000xg for 10 min, at 4°C, and the supernatants were collected and stored at -80°C. Protein 
concentration in the lysate was determined by the Bicinchoninic Acid Protein Assay (BCA) 
(Smith et al., 1985) following the instructions reported by the supplier (B-9643, Sigma, Missouri, 
USA).  
Equal amounts of protein were separated by 12% sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE). Molecular weight standards (10-250 kDa, #SM1811 Fermentas) 
were used as marker proteins. 10% β-mercapoethanol was added to the samples. Proteins were 
loaded on 12% polyacrylamide gel by electrophoresis in a Hoefer SE 250 System (Amersham 
Biosciences). After SDS-PAGE, proteins were transferred to PVDF membranes (Bio-Rad 
Laboratories, Hercules, CA, USA) by a semi-dry blotting system at 100 V for 60 min. After the 
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protein transfer step, membranes were blocked in 4% BSA (bovin serum albumin, fraction V) in 
T-TBS (0,2% Tween 20, 20 mM Tris-HCl (pH 7.5), 500 mM NaCl) and incubated overnight at 
4°C with primary antibodies. Next day, membranes were washed three times with 5% BSA-TTBS 
and incubated for 60 min with HRP-conjugated secondary antibody conjugated with peroxidase 
(Table 1). Protein bands were detected by peroxide reaction using ECL-Plus Western Blot 
detection system solutions (ECL Plus Western Blot detection reagents, GE-Healthcare 
BioSciences, Italy) and visualized by autoradiography with Hyperfilm Sigma. The relative  
Intensities of protein bands were analyzed using the NIH Image software (Scion Corporation 
Frederick, MD, USA) and normalized to α-actin.  
 
Table 1: List of antibodies used for detection of target protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Antibodies Secondary Antibodies/ HRP 
Rabbit polyclonal anti- Nrf2 (1:300), 
(C-20), Santa Cruz Biotechnology, Inc, USA. Goat anti-Rabbit (1:2000)  
P0448, Dacko Laboratories, Denmark. Rabbit polyclonal anti- α-actin (1:4000). 
A2066, Sigma Chemical, St. Louis, MO. 
Mouse monoclonal anti- αP84 (1:1000), 
Ab5E10, Abcam Inc, Cambridge, MA, USA. Rabbit anti-mouse (1:4000) 
P0260, Dacko Laboratories, Denmark. Mouse monoclonal anti- Cyclin D1 (1:200) 
Ab10540, Abcam Inc, Cambridge, MA, USA. 
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3.6 Nuclear/cytoplasmic proteins extraction 
 
 
SH-SY5Y cells and HepG2 cells at 80% confluence were treated with 140 nM Bf and 100 µM 
UCB, respectively, in a time dependent manner for 1h, 3h, 6h, and 24h. Cells treated with tBHQ 
(Sigma Aldrich) for 3h were used as positive controls. 1 mg of tBHQ were dissolved in 200 µl 
DMSO and then diluted in 1800µl PBS (DMSO : PBS at 1 : 10 ratio) to obtain a fresh stock 
solution (3mM) which is then used to reach the desired final concentration of tBHQ in medium. 
SH-SY5Y cells and HepG2 cells exposed to 0.6% DMSO and 1.8% DMSO, respectively, for 3h 
were used as negative controls.   
Nuclear extracts were obtained by using minor modification of the Dignam’s method (Dignam 
et al., 1983). Briefly, Cells at 80% confluent were washed once with PBS and collected by 
centrifugation at 800×g for 10 min. Cell Pellets were re-suspended in 150 μl of hypotonic lysis 
buffer A (10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM MgCl 2 , 0.1 mM EDTA) containing 
complete solution that added freshly before using (0.1 mM DTT, 0.5 mM PMSF, 1 mM NaF, and 
1 mM Na orthovanadate, and 1X cocktail of protease inhibitors (Sigma Aldrich), and incubated 
on ice for 10 min. Nuclei were collected by centrifugation for 10 min at 800×g, in a 
microcentrifuge at 4°C. The supernatant was removed and nuclei were then washed three times 
with the same volumes of buffer A to minimize cytoplasmic contamination. Nuclear proteins were 
extracted with 150 μl of hypertonic buffer B (10 mM Hepes (pH 7.9), 400 mM NaCl, 1.5 mM 
MgCl 2, 0.1 mM EDTA) containing complete solution that added freshly before using (0.1 mM 
DTT, 0.5 mM PMSF, 1 mM NaF, and 1 mM Na orthovanadate, and 1X cocktail of protease 
inhibitors (Sigma Aldrich), and incubating for 30 min on ice under constant stirring. Samples were 
centrifuged at 15000×g for 30 min, at 4°C and the supernatant containing nuclear proteins were 
conserved at -80. Proteins content were determined by the BCA using bovine serum albumin as 
standard (Smith et al., 1985). Purity of cytoplasmic and nuclear protein extracts was analyzed by 
Western blot using αP84 nuclear matrix protein marker. 
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3.7 RNA extraction, cDNA synthesis, and qRT-PCR (General protocol) 
 
 
SH-SY5Y cells treated with 140 nM Bf for 4h, 8h, 16h, and 24h. Primary culture of Cx 
astrocytes were treated with 140 nM for 4h and 24h. HepG2 cells were treated with 100 µM UCB 
for 24h. Cx astrocytes were treated for 8h or 24h with 140 nM Bf or 3 mM DTT (DTT was 
dissolved in PBS). Total RNA was isolated from different cells using EuroGOLD RNAPureTM 
according to the manufacture's suggestions (Euro Clone, Italy). The total RNA concentration and 
purity were quantified by spectrophotometry (DU®730, Beckman Coulter, Milan, Italy). For each 
samples, the A260/A280 ratio between 1.6 and 2.0 was considered as good RNA quality. cDNA was 
obtained from 1 µg of purified RNA using the High Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, USA) according to the manufacture's suggestions. The reaction was run in 
a thermalcycler (Gene Amp PCR System 2400, Perkin-Elmer, Boston, MA, USA) in agreement 
with the reaction protocol proposed by the manufacturer. 
Real time PCR was performed according to the iQ5 SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA, USA) protocol. PCR amplification was carried out in 25 µL reaction 
volume containing 25 ng of cDNA, 1× iQ SYBR Green Supermix (100mM KCl; 40mM Tris-HCl; 
pH: 8.4; 0.4mM each dNTP; 40 U/mL iTaq DNA polymerase; 6mM MgCl2; SYBR Green I; 
20mM fluorescein; and stabilizers) (Bio-Rad) and 250 nM of gene specific forward and reverse 
primers. The reaction was run in IQ5 real time PCR system (Bio-Rad). Primer sequences designed 
using Beacon Designer 4.02 software (PREMIER Biosoft International, Palo Alto, CA, USA) for 
the detection of desired gene and are listed in (Table 2 and Table 3). Cycling parameters were 
determined and the results were analyzed by using the comparative Ct method as the means of 
relative quantification, normalized to two references genes and expressed as 2−ΔΔCT. Melting curve 
analysis was performed to assess product specificity. 
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Table 2: List of forward and reverse primers used for detection of human target genes.   
 
Gene Accession number 
Forward primers 
5' - 3' 
Reverse primers 
5' - 3' 
Nrf2 NM_001145412 CAGCCAGCCCAGCACATC CGTAGCCGAAGAAACCTCATTG 
xCT NM_014331.3 GGTGGTGTGTTTGCTGTC GCTGGTAGAGGAGTGTGC 
Gly1 NM_201649.2 CTTCTCCTTGGTGGTCAT CATCTGGATGTCCTGGAA 
γ-GCLc NM_001498.3 AATGTCCGAGTTCAATAC AATCTGGGAAATGAAGTTAT 
γ-GCLm NM_002061.3 ATCAAACTCTTCATCATCAAC GATTAACTCCATCTTCAATAGG 
GPx1 NM_000581.2 GGCAAGGTACTACTTATCG CTCGTTCATCTGGGTGTA 
TRX1 NM_003329.3 CGTGATATTCCTTGAAGTAGA TCCTTATTGGCTCCAGAA 
NQO1 NM_000903.3 CCTCTATGCCATGAACTT TATAAGCCAGAACAGACTC 
HO-1 NM-002133.2 ATGCCCCAGGATTTGTCA CCCTTCTGAAAGTTCCTCAT 
FTH NM_002032.2 TTACCTGTCCATGTCTTAC TCATCAGTTTCTCAGCAT 
BVRA NM_000712 CGTTCCTGAACCTGATTG AAAGAGCATCCTCCAAAG 
PRDx2 NM_005809 GATTACGGCGTGCTGAAA GTCCCACAGGCAAATCAT 
SOD1 NM_000454.4 GTCCTCACTTTAATCCTCTATC TTGTCAGCAGTCACATTG 
CAT NM_001752.3 GAAGTGCGGAGATTCAAC TCCTCTGTTCCTCATTCA 
ME1 NM_002395.4 CGGCAGAGAAGAGTAAGA ACTTGTTCAGGAGACGAA 
G6PD NM_000402.3 CAGATTGAGCTGGAGAAG ATACTGGAAACCCACTCT 
ATF3 NM_001674.3 AAAAGAGGCGACGAGAAA CAGCATTCACACTTTCCAG 
ATF4 NM_001675 GGGACAGATTGGATGTTGGAGA ACCCAACAGGGCATCCAAGT 
CHOP NM_001195056 CACTCTCCAGATTCCAGTCAG AGCCGTTCATTCTCTTCAGC- 
XBP1 NM_005080 ATGGATTCTGGCGGTATTG CTGGGTCCTTCTGGGTAG 
ATF6 NM_007348 CAGAGAACCAGAGGCTTA TGCTCATAGGTCCATAGTT 
BiP NM_005347 GCACAGACAGATTGACCTATTG GTAGCACAGGAGCAC 
PERK NM-004836 TAGGGACCAAACTGTATATGA TCCATCTGAGTGCTGAAT 
GCN2 NM_001013703.2 GACAATGAAGATGAGAAC CTGGATGTATAGGTAGTG 
GAPDHa NM_002046.4 TCAGCCGCATCTTCTTTTG GCAACAATATCCACTTTACCAG 
HPRTa NM_000194 ACATCTGGAGTCCTATTGACATC CCGCCCAAAGGGAACTGATAG 
a Housekeeping genes used for normalizing the expression of target genes in SH-SY5Y cells and HepG2 
cells. 
 
 
 
Table 3: List of forward and reverse primers used for detection of rat target genes. 
   
Gene Accession number 
Forward primers 
5' - 3' 
Reverse primers 
5' - 3' 
HO-1 NM_012580.2 GGTGATGGCCTCCTTGTA ATAGACTGGGTTCTGCTTGT 
NQO1 NM_017000.3 TGCTTTCAGTTTTCGCCTTT GAGGCCCCTAATCTGACCTC 
GAPDHa NM_017008 CTCTCTGCTCCTCCCTGTTC CACCGACCTTCACCATCTTG 
β-actina NM_031144.2 GGTGTGATGGTGGGTATG CAATGCCGTGTTCAATGG 
a Housekeeping genes used for normalizing the expression of target genes in rat astrocytes primary culture.  
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3.8 GFP reporter gene assay 
 
3.8.1 Setting of transfection efficiency  
 
Constructs composed of Monster Green Fluorescence protein (GFP) under the control of 
constitutively active CMV immediate early enhancer/promoter (CMV-GFP) were used to set 
transfection conditions and efficiency. Constructs were transiently transfected into SH-SY5Y cells 
using Lipofectamine™ Reagent (Invitrogen; Merelbeke, Belgium) according to the 
manufacturer's recommendation. In brief, we tested the effects of Lipofectamine™ Reagent (from 
1 µl to 4 µl for 6h) on cells viability by MTT assay and we observed a 10% loss of cells viability 
by all concentrations (data not shown). SH-SY5Y cells were seeded in a complete growth medium 
at 70%-80% confluence in 24 multiple well. 1h before transfection, 500 µl of fresh Opti-MEM® 
I reduced serum medium (Invitrogene, Italy) were added to cells. A series of Lipofectamine™ 
Reagent range from 1µl to 4µl were diluted in 50 µl Opti-MEM® medium and incubated for 5min 
at RT. 0.8 µg of DNA construct were diluted in 50 µl Opti-MEM® medium and mixed with 
diluted lipofectamine. The Complexes (100 µl) were incubated for 20min at RT and added into 
well-containing cells for 6h and then medium was replaced with complete growth medium. GFP 
expression was analyzed 24h to 48h after transfection. 
 
3.8.2 ARE-GFP reporter transfection and UCB treatment 
 
The Cignal™ Antioxidant Response Reporter Kit (SABiosciences; Frederick, MD, USA) 
utilizes GFP under the control of ARE enhancer repeats (ARE-GFP) (enhancer: 
TCACAGTGACTCAGCAAAATT) was used to monitor the signal activation of ARE through 
Nrf2 according to handbook instructions. A reporter gene under the control of basal promoter 
element (TATA-GFP) was used as negative control. For treatment experiments, cells were 
transfected with proper construct (ARE-GFP or TATA-GFP) for 24h then incubated with assay 
medium containing 1% FBS for additional 8h. 32h post-transfection, cells were treated with 50 
µM t-BHQ or 140 nM Bf for 24h and stimulation was allowed to proceed for additional 16h before 
analysis.  
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3.8.3 Fluorescence microscopy and FACS analysis 
 
The GFP fluorescence intensity was analyzed by fluorescence microscope (Nikon eclipse 
TS100, Nikon instruments Europe B.V., Netherlands) (excitation filter 470±20 nm and emission 
filter 515 nm). GFP signal was quantified using flow cytometry FACS Calibur of an argon laser 
(488 nm excitation and filter 530±15 emission) and analyzed with CellQuest Pro software. 
Percentage of GFP positive cells was calculated by histogram analysis (showing the cell counts 
blotted with GFP fluorescence detector-highet (FL1)) or by dot blot analysis (showing the side 
scattered detector-highet (SSC-H) blotted with GFP fluorescence detector-highet (FL1)). 
Percentage of fluorescence in negative controls were considered as basal auto fluorescence value. 
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3.9 small interference RNAs (siRNAs) 
 
3.9.1 Nrf2 siRNA and PERK siRNA 
 
The experimentally validated Nrf2 siRNA (SI03246950, Qiagen, USA): Sense strand 5'-
CAUUGAUGUUUCUGAUCUATT-3'; antisense strand 5'-UAGAUCAGAAACAUCAAUGG 
G-3' against the target sequence of Nrf2 (5'-CCCATTGATGTTTCTGATCTA-3') was used to 
knockdown Nrf2 expression. The experimentally validated PERK siRNA (S102223718, Qiagen, 
USA): Sense strand 5'-CAAACUGUAUAACGGUUUATT-3'; antisense strand 5'-UAAACCGU 
UAUACAGUUUGTG-3' against the target sequence of PERK (5'-CACAAACTGTATAACGGT 
TTA-3') was used to knockdown PERK expression. siRNA against non target mRNA: Sense 
strand 5'-UUCUCCGAACGUGUCACGUdTdT-3'; antisense strand 5'-ACGUGACACGUUCG 
GAGA AdTdT-3' was used as negative control (1027310, Qiagene). 
 
3.9.2 siRNAs transfection and efficiency (General protocol) 
 
siRNA was transfected using siLentFectTM Lipid reagent (Bio-Rad) according to the 
manufacturer's recommendation. Briefly, SH-SY5Y cells were seeded at 70000 cell/cm2 in a 6 
multiwell plate. 1h before transfection, 1.25 mL of fresh Opti-MEM® I reduced serum medium 
(Invitrogene, Italy) were added to cells. A series of siRNA (25 nM, and 50 nM) were diluted in 
125 µl Opti-MEM® medium. 3 µl siLentFectTM reagent were diluted in 125 µl Opti-MEM® 
medium and mixed with diluted siRNA. The Complexs (250 µl) were incubated for 20min at RT 
and added into well-containing cells for 8h and then medium was replaced with complete growth 
medium. Nrf2 and PERK mRNA expression was analyzed 48h after transfection by qRT-PCR. 
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3.9.3 UCB treatment in siRNAs transfected cells 
 
For treatment experiments, cells were transfected with 50 nM of negative control siRNA, or 
Nrf2 siRNA, or PERK siRNA for 48h and then treated with 0.6% DMSO or 140 nM Bf for 
additional 4h to 24h. mRNA were extracted and expression of target genes were then analyzed by 
qRT-PCR.  
Same strategy was applied to check the effects of Nrf2 siRNA or PERK siRNA on cells 
viability upon UCB exposure. Cells transfected with each type of siRNA (Control, or Nrf2, or 
PERK) for 48h were treated with 140 nM Bf for 4h or 24h and then cells viability was assessed 
by MTT. 
 
 3.9.4 Applying of L-Buthionine sulfoximine in Nrf2 siRNA cells 
 
SH-SY5Y cells transfected with control siRNA or Nrf2 siRNA were pre-treated or not-treated 
(control) with 0.1 mM of L-Buthionine-sulfoxamine (BSO, a glutathione synthesis inhibitor) 
(Sigma Aldrich) for 2h, followed by incubation with 0.6% DMSO (control), or 0.2 mM H2O2 
(positive control), or 140 nM Bf for additional 24h (BSO was maintained during incubation time). 
Cells viability was then determined by MTT assay. 
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3.10 Evaluation of up-stream signaling for Nrf2/HO-1 activation 
 
3.10.1 Applying of antioxidant N-acetylcysteine before UCB treatment 
 
SH-SY5Y cells at 80% of confluence were pre-treated with 0.5 mM of exogenous antioxidant 
N-acetylcysteine (NAC, a glutathione precursor) (Sigma Aldrich) for 1h, followed by incubation 
with medium (control), 0.6% DMSO (control), or 0.2 mM H2O2 (positive control), or 40 nM Bf 
(negative control), or 140 nM Bf for additional 16h (NAC was maintained during incubation time). 
RNA from treated cells were extracted and genes were analyzed by qRT-PCR.   
 
3.10.2 Applying of specific signaling inhibitors before UCB treatment 
 
SH-SY5Y cells were pre-treated with specific signaling pathway inhibitors for 1h: PI3K 
inhibitor LY-294002 (10 μM), MEK1/2-ERK1/2 inhibitor PD98059 (20 μM), c-Jun NH2-terminal 
kinases (JNK) inhibitor SP600125 (10 μM), p38α MAPK inhibitor SB203580 (10 μM) and PKC 
inhibitor GF109203X (10 μM). Concentration of inhibitors were used as described by others 
(Genc et al., 2010). Beside the GF109203X which was purchased from Cyaman Chemicals (Italy), 
all other inhibitors were obtained from Selleckchem (Italy). After 1h, cells were exposed to 0.6% 
DMSO or 140 nM Bf for additional 16h in the presence or absence (control) of specific inhibitors 
(specific inhibitors were maintained during incubation time). Expression of target genes were 
analyzed by qRT-PCR and normalized to cells incubated only with specific inhibitors. 
 
3.11 Statistical analysis 
 
Data were obtained from at least three independent experiments and are expressed as mean ± 
SD. Statistical analysis was performed using student's t-test. * P < 0.05, ** P < 0.01, *** P < 
0.001 were considered as significant. 
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4. RESULTS 
 
4.1 Effects of UCB treatment on SH-SY5Y cells  
 
4.1.1 Cells viability  
 
To evaluate the sensitivity of SH-SY5Y cells to UCB toxicity, cells were exposed to a pro-
oxidant concentration of UCB (30 µM of total UCB or 140 nM Bf) in a time dependent manner 
from 1h to 24h. Cells show a reduction of cell viability (measured by MTT) to about 40% starting 
1h to 4h after Bf treatment and reached plateau till 24h. It was evident that most of the cells are 
able to overcome UCB toxicity at high concentration and after long time of Bf exposure (24h) 
(Fig 9). Based on this observation we studied the molecular events associated with UCB toxicity 
and the possible pathways involved in cell protection (or adaption) against UCB toxicity. 
 
 
 
 
Figure 9: Cells viability measured by MTT assay. Cells were exposed to medium (control), or 0.6% 
DMSO (control), or 140 nM Bf for 1h, 4h, 8h, 16h, and 24h and viability was assessed by MTT test. *** 
P < 0.001. 
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4.1.2 UCB increases intracellular ROS level 
 
We have previously demonstrated the involvement of OS in mediating cell death by UCB in 
SH-SY5Y cells after 24h of exposure (Deganuto et al., 2010). In the present work, we observed 
an increased level of intracellular ROS levels in cells treated with 140 nM Bf (1.9 folds) as 
compared to those treated with 0.6% DMSO for 60 min (1 fold). Cells treated with 0.2 mM H2O2 
for 60 min showing an increased intracellular ROS levels were used as positive control (1.5 folds) 
(Fig 10).  
 
 
                  
Figure 10: UCB increases intracellular ROS level. Intracellular ROS level in SH-SY5Y cells treated 
with 0.6% DMSO (control), or 140 nM Bf, or 0.2 mM H2O2 (positive control) for 60 min. Intracellular ROS 
levels was measured by FACS analysis quantifying the DCF fluorescence derivative. * P < 0.05. 
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4.2 Effects of UCB treatment on Nrf2 pathways in SH-SY5Y cells 
 
4.2.1 Nrf2 expression  
4.2.1.1 Nrf2 mRNA expression in SH-SY5Y 
 
Because ROS is a direct activator of Nrf2 pathway, that represents the primary response to 
OS, we investigated whether UCB-mediated ROS generation also activates Nrf2 pathway as an 
adaptive response. SH-SY5Y cells treated with 140 nM Bf showed an up-regulation (relative to 
DMSO control) of Nrf2 mRNA expression after 8h maintained until 16h (1.7 fold and 2.2 folds, 
respectively). This up-regulation is not significant at 24h indicating the transient induction of the 
Nrf2 gene (Fig 11).  
 
                                
Figure 11: UCB up-regulates Nrf2 mRNA. SH-SY5Y cells were treated with 0.6% DMSO or 140 nM 
Bf for 4h, 8h, 16h, and 24h. Nrf2 mRNA expression was analyzed by qRT-PCR. mRNA expression was 
normalized to GAPDH and HPRT and is represented as relative to cells incubated with 0.6% DMSO for 
4h. * P < 0.05. 
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4.2.1.2 Nrf2 protein translocation in SH-SY5Y  
 
The key issue of Nrf2 pathway activation is the translocation (or accumulation) of Nrf2 
proteins in the nucleus. In order to assess the purity of nuclear-cytoplasmic extractions we checked 
the nuclear marker protein αP84 by Western blot. It resulted detectable only in the nuclear extract 
(Fig 12A). Next, both extracts were subjected to SDS-PAGE for Nrf2 protein analysis. We were 
not able to detect Nrf2 protein in cytoplasmic extract (data not shown) and this is maybe due to 
the low level of Nrf2 protein under the basal state. Nrf2 antibodies recognize several bands. In 
order to avoid un-specificity problems, cells were treated with tBHQ, an Nrf2 inducer that is used 
as a positive control, and the Nrf2 band was recognized at 100 KDa as already described (Kang 
et al., 2002; Li et al., 2005). A nuclear accumulation of Nrf2 proteins (100 KDa) was found after 
Bf treatment with a peak increment between 3h (4.7 folds) and 6h (6.6 folds) and the return to 
basal after 24h (0.7 fold). Nrf2 proteins quantification was normalized to actin and represented as 
relative expression to cells incubated with 140 nM Bf for 1h (1 fold). 50 µM of tBHQ increased 
the nuclear accumulation of Nrf2 proteins after 3h of treatment (4.3 folds) while cells incubated 
with 0.6% DMSO for 3h show no bands for Nrf2 proteins (Fig 12B and Fig 12C). 
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Figure 12: UCB mediates nuclear accumulation of Nrf2 proteins in SH-SY5Y cells. (A) Western blot 
analysis for nuclear marker proteins (αP84) from nuclear (N) and cytoplasmic extracts. (B) Representative 
Western blot analysis for Nrf2 and α-actin (42KDa) proteins in nuclear extracts from SH-SY5Y cells 
treated with 0.6% DMSO for 3h, 50 µM tBHQ for 3h (positive control), and 140 nM Bf (equivalent to 30 
μM UCB) for 1h, 3h, 6h and 24h. (C) Expression of nuclear Nrf2 proteins was normalized to α-actin and 
represented as relative expression to cells incubated with 140 nM Bf for 1h. ** P < 0.01, *** P < 0.001. 
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4.2.1.3 Nrf2 protein translocation in HepG2 cells 
 
We checked for the nuclear translocation of Nrf2 by UCB in HepG2 cells by treating them 
with 100 µM of UCB for 1h, 3h, 6h, and 24h. Results showed a time dependent accumulation of 
nuclear Nrf2 proteins (100 KDa) starting after 1h with maximum that occurs between 3h (2 folds) 
and 6h (4 folds) and the return to basal after 24h. Cells treated with 100 µM tBHQ for 3h were 
used as a positive control and showed an increase of nuclear Nrf2 proteins (2.3 folds) while no 
bands were detected in cells incubated with 1.8% DMSO for 3h (negative control). Nrf2 proteins 
were normalized to actin and represented as relative expression to cells incubated with 100 µM 
UCB for 1h (Figure 13A and 13B).  
 
               
       
Figure 13: UCB mediates nuclear accumulation of Nrf2 proteins in HepG2 cells. (A) Western blot 
analysis for Nrf2 and α-actin proteins in nuclear extracts from HepG2 cells treated with 1.8% DMSO for 
3h, 100 µM tBHQ for 3h (positive control), and 100 μM UCB for 1h, 3h, 6h, and 24h. (B) Expression of 
nuclear Nrf2 protein was normalized to α-actin and represented as relative expression to cells incubated 
with 100 µM UCB for 1h. *** P < 0.001. 
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4.2.2 ARE-GFP reporter gene assay  
4.2.2.1 Transfection efficiency 
 
We set the transfection efficiency on SH-SY5Y cells using the constitutively active CMV-
GFP plasmid. When cells transfected with fixed amount of plasmid (0.8µg) using different 
concentration of lipofectamine™ (2µl, 3µl, or 4µl), the transfection efficiency was about 30%, 
40%, or 50%, respectively (Figure 14A). When cells transfected with fixed amount of 
lipofectamine™ (4µl) using different concentration of plasmid (0.5µg, 0.8µg, or 1.2µg), the 
transfection efficiency was about 50%, 60%, or 70%, respectively (Figure 14B). Based on this, 
we decided to transfect cells with 0.8µg using 3µl lipofectamine™. 
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Figure 14: Transfection efficiency. (A) Lipofectamine optimization: Cells were transfected using a 
serial dilution of Lipofectamine (LipoTM from 2 µl to 4 µl) and 0.8 µg of the constitutively active plasmid 
CMV-GFP. (B) Plasmid optimization: Cells were transfected with serial dilution of CMV-GFP (0.5 µg, 
or 0.8 µg, or 1.2 µg) using 4 µl of Lipo™. GFP was visualized by immunofluorescence microscopy (IF 
microscopy, magnification 10X, upper panel) and quantified by FACS analysis (lower panel, show the cell 
counts blotted with GFP fluorescence detector-highet (FL1-H)). % of GFP positive cells were reported for 
each condition. Cells incubated with Medium or Lipo™ (Mock) we used as controls. 
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4.2.2.2 UCB induces ARE-GFP expression 
 
To confirm Nrf2 pathway activation upon UCB exposure, a reporter gene composed of GFP 
under the control of ARE cis-elements repeats was used. SH-SY5Y cells transfected with ARE-
GFP constructs were treated with 0.6% DMSO (negative control), 50 µM tBHQ (positive control), 
or 140 nM Bf (Fig 15A). Green fluorescence protein (GFP) was detected by immunofluorescence 
microscopy (IF) in cells treated with tBHQ and Bf while no signal was detected in DMSO-treated 
cells (Fig 15A. upper panel). The percentage of GFP positive cells quantified by FACS analysis 
35% in tBHQ and 46% in Bf treated cells, compared to 5% (basal fluorescence) in DMSO treated 
cells (Fig 15A. lower panel). Cells transfected with TATA-GFP constructs  treated with 50 μM 
tBHQ (negative control) showed 7% of basal fluorescence while cells transfected with CMV-GFP 
constructs showed 80% of GFP positive, were used as positive controls for GFP signal (Fig 15B).  
 
 
 
 
 
 
Figure 15: UCB activates Nrf2 pathway and induces expression of ARE-GFP reporter gene (A) SH-
SY5Y Cells transfected with ARE-GFP reporter were treated with 0.6% DMSO (control), or 50 µM tBHQ 
(positive control), or 140 nM Bf for 24h (left panel). After 40h of stimulation, GFP signal was visualized 
by immunofluorescence microscopy (IF, upper panel) and quantified using FACS analysis (Dot blot 
histogram show the side scattered detector-highet (SSC-H) blotted with GFP fluorescence detector-highet 
(FL1-H)) (lower panel). Microscope magnification: objective 20X. (B) Cells transfected with negative 
control (TATA-GFP) show a 7% of basal fluorescence, while cells transfected with (CMV-GFP) were used 
as positive control for GFP signal.  
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4.2.3 Expression of Nrf2 target genes candidates  
4.2.3.1 Genes involved in Glutathione homeostasis 
 
Compared to DMSO controls, cells treated with 140 nM Bf showed a significant mRNA up-
regulation for: (A) xCT starting after 8h (10 folds), increased at 16h (20 folds), and remains up-
regulated till 24h (8 folds). (B) Gly1 starting after 8h and remains till 24h (13 folds). (C) γGCL-
m induced (3 folds) at 16h and 24h. (D) γGCL-c induced only at 16h (2.3 folds). (E) TRX1 induced 
at 24h (2 folds). No change on the expression of (F) GPx1 was detected (Fig 16). 
 
 
Figure 16: UCB induces expression of different genes involved in GSH homoeostasis. SH-SY5Y cells 
were treated with 0.6% DMSO or 140 nM Bf for 4h, 8h, 16h, and 24h. mRNA expression of (A) xCT, (B) 
Gly1, (C) γGCL-m, (D) γGCL-c, (E) TRX1, and (F) GPx1 was normalized to GAPDH and HPRT and 
represented relative to cells incubated with 0.6% DMSO for 4h. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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4.2.3.2 Genes involved in antioxidant/detoxification 
 
Compared to DMSO controls, cells treated with 140 nM Bf showed a significant mRNA up-
regulation for: (A) NQO1 induced at 16h and 24h (2.3 folds and 5 folds, respectively). (B) HO-1 
up-regulated at 16h and 24h (30 folds). (C) FTH induced only at 24h (3 folds). No changes on the 
expression of (D) SOD1 and (E) CAT was detected while (F) PRDx2 was down-regulated by 62% 
after 24h of Bf treatment (Fig 17). 
 
 
 
 
Figure 17: UCB induces expression of NQO1, HO-1, and FTH. SH-SY5Y cells were treated with 0.6% 
DMSO or 140 nM Bf for 4h, 8h, 16h, and 24h. mRNA expression of (A) NQO1, (B) HO-1, (C) FTH, (D) 
SOD1, (E) CAT, and (F) PRDx2 was normalized to GAPDH and HPRT and represented relative to cells 
incubated with 0.6% DMSO for 4h. * P < 0.05, ** P < 0.01. 
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4.2.3.3 Genes involved in NADPH homeostasis 
 
Cells treated with 140 nM Bf showed a significant up-regulation to about (2.5 folds) of mRNA 
expression of (A) ME1 and (B) G6PD at 24h compared to controls (Fig 18). 
 
 
 
Figure 18: UCB induces expression of  (A) ME1 and (B) G6PD. SH-SY5Y cells were treated with 0.6% 
DMSO or 140 nM Bf for 4h, 8h, 16h, and 24h. mRNA expression was normalized to GAPDH and HPRT 
and represented relative to cells incubated with 0.6% DMSO for 4h. * P < 0.05, *** P < 0.001. 
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4.2.3.4 Transcription factor involved in stress response 
 
Cells treated with 140 nM Bf showed a significant up-regulation of ATF3 starting after 4h (8 
folds) and remain all over the times (about 30 folds), compared to controls (Fig 19). 
 
 
                                           
Figure 19: UCB induces expression of ATF3. SH-SY5Y cells were treated with 0.6% DMSO or 140 
nM Bf for 4h, 8h, 16h, and 24h. mRNA expression of ATF3 was normalized to GAPDH and HPRT and 
represented relative to cells incubated with 0.6% DMSO for 4h. * P < 0.05, ** P < 0.01. 
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4.2.3.5 Nrf2 target genes expression summary 
 
Genes were classified as early (4h – 8h) and late response (16h – 24h) and their expression 
levels summarized in (Table 4). Genes that are up-regulated by UCB were highlighted with green 
color, while the down-regulated were highlighted with blue color and.  
 
 
Table 4: UCB causes a general induction of antioxidant and stress response genes in SH-SY5Y cells.  
mRNAa Early response Late response 
Genes 
4h 8h 16h 24h 
0.6% 
DMSO 
140nM 
Bf 
0.6% 
DMSO 140nM Bf 
0.6% 
DMSO 140nM Bf 
0.6% 
DMSO 140nM Bf 
xCT 1  3 ± 2 1.1 ± 0.7 10 ± 3* 0.8 ± 0.5 20 ± 2.2*** 0.8 ± 0.2 8 ± 0.8** 
Gly1 1 1.6 ± 0.3 2 ± 1.3 13± 3* 1 ± 0.1 13 ± 4.8*** 1.2 ± 0.3 14 ± 2.5** 
γGCL-c 1 1 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 1.2 ± 0.2 2 ± 0.2** 1.5 ± 0.1 1.4 ± 0.5 
γGCL-m 1  1 ± 0.1 1 ± 0.4 1.2 ± 0.3 0.9 ± 0.2 3 ± 0.3*** 1 ± 0.3 3 ± 0.8* 
TRX1 1 0.7 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.5 ± 0.2 0.4 ± 0.16 0.8 ± 0.1 2 ± 0.1 
NQO-1 1 1 ± 0.4 1 ± 0.3 1 ± 0.4 1 ± 0.3 2 ± 0.6* 1 ± 0.5 5 ± 0.6*** 
HO-1 1 1.6 ± 0.3 1.7 ± 0.7 3.9 ± 1.8 1 ± 0.6 30 ± 7.5** 1 ± 0.5 32 ± 8.2** 
FTH 1  1 ± 0.1 0.8 ± 0.3 0.8 ± 0.2 1 ± 0.2 1.9 ± 0.7 1 ± 0.3 3 ± 0.6* 
ME1 1 1 ± 0.2 0.9 ± 0.3 1.3 ± 0.1 0.9 ± 0.2 1.7 ± 0.4 1.2 ± 0.1 2.5 ± 0.1*** 
G6PD 1 1.5 ± 0.2 1 ± 0.1 0.9 ± 0.2 1.2 ± 0.4 1 ± 0.02 1 ±0.02 2.4 ± 0.5 
ATF3 1 8 ± 2.5** 1.8 ± 1.4 39 ± 11** 1 ± 0.3 42 ± 8**  1 ± 0.3 31 ± 5*** 
PRDx2 1 0.9 ± 0.3 1 ± 0.4 0.9 ± 0.1 1 ± 0.1 1 ± 0.3 1.4 ± 0.2 0.6 ± 0.1 * 
Genes differentially expressed upon UCB exposure (Green = up-regulated; Blue = down-regulated).  
a mRNA expression of target genes was normalized to GAPDH and HPRT and relative to DMSO treated 
cells at each indicated times. * P < 0.05, ** P < 0.01, *** P < 0.01. 
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4.2.3.6 HO-1 and NQO1 expression in HepG2 cells 
 
In order to correlate the nuclear accumulation of Nrf2 in HepG2 cells upon UCB treatment 
(Fig 13) with the expression of its target genes, we analyzed the expression of two putative marker 
for Nrf2 pathway activation (HO-1 and NQO1). mRNA expression of HO-1 and NQO1 were 
induced 4 folds in UCB treated cells compared to DMSO treated controls (Fig 20). 
 
 
 
 
Figure 20: UCB induces mRNA expression of (A) HO-1 and (B) NQO1 in HepG2 cells. HepG2 cells 
were treated with 1.8% DMSO or 100 µM UCB for 24h. mRNA expression was normalized to GAPDH 
and HPRT and represented relative to DMSO treated cells. ** P < 0.01. 
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4.2.4 Nrf2 small interference RNA (Nrf2 siRNA) 
4.2.4.1 Nrf2 siRNA efficiency  
 
siRNA efficiency toward Nrf2 was calculated by qRT-PCR after 48h of transfection. 25 nM 
or 50 nM of Nrf2 siRNA down-regulated Nrf2 mRNA to about 50% and 60%, respectively, as 
compared to 50 nM control siRNA (Fig 21). Cells incubated with medium or 3 µl silentFect™ 
were used as additional controls.  
 
 
 
 
Figure 21: Nrf2 siRNA decreases Nrf2 mRNA expression. Effects of control siRNA (50 nM, Ct siRNA; 
horizontal lines) and Nrf2 siRNA (25 nM or 50 nM; squares) on Nrf2 mRNA expression in SH-SY5Y 
cells. Cells incubated with 3µl siFect or medium were used as additional controls. ** P < 0.01. 
 
Nrf2 was also reported to regulate the basal expression of its target genes. The functionality 
of Nrf2 siRNA was also confirmed by analyzing the basal expression of HO-1 and NQO1. HO-1 
and NQO1 mRNA expression were reduced to about 50% by Nrf2 siRNA compared to control 
siRNA immediately after 48h of transfection (data not shown).  
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4.2.4.2 Effects of Nrf2 siRNA on Nrf2 target genes expression upon UCB exposure 
 
The mRNA expression of HO-1 and NQO1, after DMSO treatment, was reduced to about 45% 
and 40% by Nrf2 siRNA compared to control siRNA (Fig 22A and B). The induction of HO-1 
and NQO1 mRNA by UCB was decreased by 75% (Fig 22A) and 54% (Fig 22B), respectively, 
in the Nrf2 siRNA transfected cell as compared to control siRNA. Even though no change on the 
basal expression of FTH was observed, the induction of FTH by UCB was reduced by 40% (Fig 
22C). No changes were detected between control siRNA and Nrf2 siRNA in the expression of 
Nrf2, xCT, Gly1, γGCL-c, γGCL-m, ME1, ATF3, and TRX1, upon DMSO and UCB treatment 
(Fig 22D). 
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Figure 22: Nrf2 siRNA decreases the mRNA induction of (A) HO-1, (B) NQO1, and (C) FTH by 
UCB. SH-SY5Y cells transfected with 50 nM of control siRNA (horizontal lines) or Nrf2 siRNA 
(squares) for 48h followed by exposure to 140 nM Bf or 0.6% DMSO for additional 24h before qRT-
PCR analysis. (D) mRNA expression of other Nrf2 target genes in cells transfected with Nrf2 or control 
siRNA and then treated with DMSO or Bf for 24h. * P < 0.05, ** P < 0.01.       
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4.2.4.3 Effects of Nrf2 siRNA on cell viability upon UCB exposure 
 
 To test whether Nrf2 siRNA will affect cells viability upon Bf exposure, SH-SY5Y cells 
transfected with control siRNA or Nrf2 siRNA were treated with DMSO 0.6%, 0.2 mM H2O2 
(positive control) or 140 nM Bf for 24h and cell viability was assessed by MTT assay. In the 
control siRNA transfected cells 0.2 mM H2O2 and 140 nM Bf reduced cell viability to 71% and 
68%, respectively. Nrf2 siRNA further reduced cell viability to 51% upon H2O2 exposure while 
no change was detected in Bf treated cells. (Fig 23, left panel). To test the hypothesis that the 
cells were still able to maintain redox state through the induction of Nrf2-independent genes 
mainly those involved in GSH homeostasis, siRNA transfected cells were pre-treated with 0.1 
mM BSO (a specific inhibitor for γGCL) for 2h followed by exposure to 0.6% DMSO, 0.2 mM 
H2O2, or 140 nM Bf for additional 24h. In Nrf2 siRNA transfected cells, BSO treatment further 
reduced cell viability to 36% and 43% after exposure to 0.2 mM H2O2 and 140 nM Bf as compared 
to 66% and 70% in control siRNA (Fig 23, right panel). Cells transfected with control siRNA or 
Nrf2 siRNA, incubated with BSO and treated with 0.6% DMSO, show 95% and 90%, 
respectively, of viability compared to cells not incubated with BSO (Fig 23). 
 
 
 
Figure 23: Nrf2 siRNA by itself is not sufficient to increase cell sensitivity to UCB exposure, but do 
in the presence of BSO. Cell viability (MTT) in SH-SY5Y cells transfected with control siRNA 
(horizontal lines) or Nrf2 siRNA (squares) with (right panel) and without (left panel) pre-treatment of 0.1 
mM BSO for 2h (+BSO and – BSO, respectively) before 0.6% DMSO, or 0.2 mM H2O2, or 140 nM Bf 
exposure for additional of 24h (BSO was maintained during 24h). *** P < 0.001.      
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4.2.5 Up-stream signaling involved in Nrf2/HO-1 activation 
4.2.5.1 Effects of antioxidant (NAC) on the induction of HO-1  
 
In order to clarify the contribution of OS in the activation of Nrf2/HO-1 axis, SH-SY5Y cells were 
pre-treated with exogenous antioxidant (0.5 mM NAC) before UCB exposure. Cells treated with 0.2 mM 
H2O2 were used as positive controls. HO-1 mRNA expression was induced 3 folds in SH-SY5Y cells 
treated with 0.2 mM H2O2, but only 1.5 folds in the presence of NAC. Similarly, HO-1 mRNA expression 
was induced (25 folds) by 140 nM Bf treatment and 10 folds in the presence of NAC. Cells treated with 
0.6% DMSO or 0.5 mM NAC or 40 nM Bf (a non-toxic concentration of UCB) were used as negative 
controls (Fig 24). 
 
 
Figure 24: Antioxidant NAC reduces the induction of HO-1 by UCB. HO-1 mRNA expression after 
16h in SH-SY5Y cells treated with 0.6% DMSO (control); 40 nM Bf (negative control); 0.5 mM NAC 
(control); 0.2 mM H2O2 (positive control) or 140 nM Bf in the absence or presence of 0.5 mM NAC. * P 
< 0.05, ** P < 0.01.  
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4.2.5.2 Effects of different kinase inhibitors on the induction of HO-1  
 
To investigate the upstream signaling kinase(s) involved in Nrf2/HO-1 induction by UCB, the 
same approach was proceeded using different specific kinase inhibitors. Results demonstrated that 
HO-1 mRNA levels are 45 fold more in cells treated with 140 nM Bf express than in control cells 
treated with DMSO. HO-1 mRNA expression was reduced to 9 folds, 27 folds, and 34 folds in the 
presence of PKC, P38α, and MEK1/2 inhibitors, respectively. The expression of HO-1 was not 
significantly changed using inhibitors for JNK and PI3K pathways (Fig 25). 
 
 
Figure 25: PKC, MEK1/2, and p38α inhibitors reduce HO-1 induction by UCB. HO-1 mRNA 
expression after 16h in SH-SY5Y cells treated with 140 nM Bf in the absence or presence of specific 
signaling pathway inhibitors: PKC (GF 109203X), MEK1/2 (PD 98059), p38α (SB 203570), JNK (SP 
600125), and PI3K (LY 294002). mRNA relative expression was normalized to cells incubated only with 
vehicles composed of 0.6% DMSO or specific chemical inhibitors alone. * P < 0.05, ** P < 0.01.   
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4.3 Effects of UCB treatment on ER-stress in SH-SY5Y cells 
 
4.3.1 ER stress biomarkers 
 
Our results indicated that ATF3 up-regulation represents the earliest response to UCB toxicity 
(section 4.3.2.5) and its expression was independent on Nrf2 (section 4.2.4.2). ATF3 is induced 
by several stimuli (Hai et al., 1999), however the first signaling to consider is the ER stress, 
because ATF3 is suggested as a putative marker for UPR (Jiang et al., 2004). We extended this 
observation by analyzing the downstream signaling of UPR.   
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4.3.1.1 UPR signaling components  
 
PERK signaling was proposed as the major arm of UPR that involved translation inhibition, 
ATF3, ATF4, and CHOP induction, and loss of cyclin D1 protein. After 4h of UCB exposure, we 
observed that ATF3 (Fig 26A), CHOP (Fig 26B), and ATF4 (Fig 26C), mRNAs were induced (8 
folds, 10 folds, and 2 folds, respectively) compared to DMSO controls. The up-regulation was 
maintained all over the 24 h of treatment with the increasing of CHOP (90 folds at 24h). 
Furthermore, we observed a dramatic loss of cyclin D1 proteins (Fig 26D) by 50% starting after 
1h of UCB exposure, reaching 70% at 4h and 90% at 24h.  
 
 
 
Figure 26: UCB induces mRNA expression of (A) ATF3, (B) CHOP, and (C) ATF4. SH-SY5Y cells 
were treated with 0.6% DMSO or 140 nM Bf for 4h, 8h, 16h, and 24h. mRNA expression was normalized 
to GAPDH and HPRT and represented relative to cells incubated with 0.6% DMSO for 4h. (D) UCB 
down-regulates Cyclin D1 protein SH-SY5Y cells were treated with 0.6% DMSO for 4h (control), or 
140 nM Bf for 1h, 4h, 8h, and 24h. Cyclin D1 total proteins were analyzed by Western blot, normalized to 
α-actin, and represented as the ratio. Expression was relative to cells incubated with 0.6% DMSO for 4h 
(Control). * P < 0.05, ** P < 0.01.   
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IRE1 and ATF6 signaling represent the other two arms of UPR that involved in the activation 
of XBP1 and ATF6, respectively. Compared to DMSO controls, induction of XBP1 (12 folds) 
(Fig 27A) started after 8h of UCB treatment and is maintained till 24h. ATF6 mRNA was induced 
(2 folds) (Fig 27B) after 8h of UCB exposure with a time dependent increase of induction that 
reached 6 folds at 24h. Furthermore, mRNA expression of BiP (Fig 27C) – a general marker of 
ER stress – begin to be induced (4 folds) after 8h of UCB exposure and the induction increases in 
a time dependent manner that reaches 12 folds at 24h. 
 
 
 
 
Figure 27: mRNA expression of (A) XBP1, (B) ATF6, and (C) BiP. SH-SY5Y cells were treated with 
0.6% DMSO or 140 nM Bf for 4h, 8h, 16h, and 24h. mRNA expression was normalized to GAPDH and 
HPRT and represented relative to cells incubated with 0.6% DMSO for 4h. * P < 0.05, ** P < 0.01, *** P 
< 0.001. 
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4.3.2 PERK small interference RNA (PERK siRNA) 
4.3.2.1 PERK siRNA efficiency 
 
siRNA efficiency toward PERK was calculated by qRT-PCR after 48h of transfection. 25 nM 
or 50 nM of PERK siRNA down-regulated PERK mRNA to about 55% and 70%, respectively, as 
compared to control siRNA (Fig 28). Cells incubated with 3 µl silentFect™ were used as 
additional controls.  
 
                    
Figure 28: PERK siRNA decreases PERK mRNA expression. Effects of control siRNA (25 nM, or 50 
nM, Ct siRNA; horizontal lines) and PERK siRNA (25 nM or 50 nM; bubbles) on PERK mRNA expression 
in SH-SY5Y cells. Cells incubated with 3µl siFect were used as additional control. *** P < 0.001.   
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4.3.2.2 Effects of PERK siRNA on the induction of ER-stress genes 
 
To evaluate the possible role of PERK signaling in the induction of several genes. SH-SY5Y 
cells were transfected with PERK siRNA and then exposed to UCB for 4h and 16h. Effects of 
PERK siRNA on the induction of several genes by UCB is reported in Table 5.  
As already, demonstrate at the basal state (DMSO treatment) PERK siRNA reduced the 
expression of PERK to about 70% compared to control siRNA. The same seems to occur for ATF-
3 and HO-1 that showing a trend of down-regulation by PERK siRNA which needs to be 
confirmed in more experiments. PERK is induced by UCB about 5 folds (compared to DMSO) in 
both control siRNA and PERK siRNA at 4h and 16h. No clear change was observed on the 
induction of ATF3, ATF4, CHOP, xCT and HO-1 by UCB in the presence of PERK siRNA 
compared to control siRNA. These results suggest that ATFs/CHOP induction is PERK 
independent and maybe related to another signaling pathway. 
 
Table 5: Effects of PERK siRNA on the induction of several genes by UCB in SH-SY5Y cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a mRNA expression of PERK, ATF3, ATF4, CHOP, and HO-1 in control siRNA and PERK siRNA 
transfected cells treated with 0.6% DMSO or 140nM Bf for 4h or 16h. Expressions were normalized to 
GAPDH and HPRT and relative to control siRNA-DMSO treated cells at the indicated times (experiment 
n=1).  
 
 
 4h 16h 
mRNA 
Rel. 
Exp. a  
Control siRNA PERK siRNA Control siRNA PERK siRNA 
0.6% 
DMSO 
140nM 
Bf 
0.6% 
DMSO 
140nM 
Bf 
0.6% 
DMSO 
140nM 
Bf 
0.6% 
DMSO 
140nM 
Bf 
PERK 1  4.39 0.3 1.42 1 5.13 0.3 1.57 
ATF3 1 47 0.5 40 1 41 0.7 31 
ATF4 1 5.3 1 5 1 5 1.7 4.7 
CHOP 1  41 1 47 1 32 1.4 23 
xCT     1 26 1 28 
HO-1     1 51 0.5 31 
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4.3.2.3 Effects of UCB and PERK siRNA on GCN2 expression 
 
We analyzed the mRNA expression of GCN2, an important signaling that work in 
coordination with PERK (see section 1.5.3) after 4h (Fig 29A) and 16h (Fig 29B) of UCB 
treatment. At the basal state (DMSO treatment), cells transfected with PERK siRNA showed a 
trend for GCN2 mRNA down-regulation at 4h (Fig 29A) and 16h (Fig 29B) compared to control 
siRNA. 4h of UCB treatment induced GCN2 mRNA in PERK siRNA but not in control siRNA. 
After 16h of UCB treatment, GCN2 mRNA is reduced both in PERK and control siRNA. These 
results are to be considered preliminary due to n=1. 
 
 
Figure 29: PERK siRNA induces GCN2 mRNA by UCB at (A) 4h while down-regulates it at (B) 16h. 
SH-SY5Y cells transfected with 50 nM of control siRNA (horizontal lines) or PERK siRNA (bubbles) for 
48h followed by exposure to 140 nM Bf or 0.6% DMSO for additional 4h or 16h. mRNA expression of 
GCN2 was normalized to GAPDH and HPRT and relative to control siRNA-DMSO treated cells at the 
indicated time (experiment n=1). 
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4.4 UCB treatment in Primary culture of rat cortical astrocytes 
 
4.4.1 mRNA expression of HO-1, NQO1, ATF3, and CHOP 
 
Compared to cells treated with 0.6% DMSO, mRNA expression of HO-1 (Fig 30A) and NQO1 
(Fig 30B) was about 2 folds up-regulated in Cx astrocytes treated with 30 µM UCB (140 nM Bf) 
for 24h, while no significant change was observed on xCT mRNA expression (Fig 30C). Cx 
astrocytes treated with 50 µM tBHQ (Nrf2 inducer) showed an up-regulation for HO-1 (8 folds), 
NQO1 (10 folds), and xCT (7 folds), compared to controls (Fig 30A, 30B, and 30C, respectively). 
 
  
 
Figure 30: UCB induces mRNA expression of (A) HO-1 and (B) NQO1 but not (C) xCT in Cortex 
astrocytes. Primary culture of Cx astrcoytes were treated with 0.6% DMSO, or 30 µM UCB, or 50µM 
tBHQ for 24h. mRNA expression was normalized to GAPDH and actin and represented relative to DMSO 
treated cells. *P < 0.05, ** P < 0.01.      
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mRNA expression of ATF3 (Fig 31A), CHOP (Fig 31B), and xCT (Fig 31C) was not changed 
in Cx astrocytes treated with UCB for 8h, or 24h (data not shown). On the contrary, Dithiothreitol 
(DTT) (an ER stress inducer) induced the expression of ATF3, CHOP, and xCT, compared to 
controls (Fig 31A, 31B, and 31C, respectively). 
 
 
 
Figure 31: UCB does not induce mRNA expression of (A) ATF3, (B) CHOP, and (C) xCT after 8h of 
UCB treatment in Cortex astrocytes. Primary culture of Cx astrcoytes were treated with 0.6% DMSO, 
or 30 µM UCB, or 3mM DTT (waves) for 8h. mRNA expression was normalized to GAPDH and actin and 
represented relative to DMSO treated cells.   
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5. DISCUSSION 
 
5.1 SH-SY5Y cells as a model to study bilirubin neurotoxicity  
 
 
One problem facing researchers working in the field of UCB neurotoxicity is to choose and to 
find the suitable/sensitive cellular model to study and a clinically significant range of UCB 
concentration to treat the cells (Ngai et al., 2000; Calligaris et al., 2007). Several published in vitro 
toxicity findings maybe clinically irrelevant to the in vivo conditions under hyperbilirubinemia, 
such as those performed in liver derived cell lines (Oakes and Bend, 2005), yet UCB-induced liver 
toxicity/damage has never been reported by clinicians. 
The SH-SY5Y cell line has become a popular and powerful cellular model in studies related 
to neurotoxicity and neurodegenerative disease, because these cells possess many biochemical 
and functional properties of neurons (XIE Hong-rong et al., 2010; Agholme et al., 2010). Based 
on the previous works performed in our laboratories we selected undifferentiated SH-SY5Y cells 
as a suitable model for several reasons: 
1. Undifferentiated neurons revealed to be particularly susceptible to UCB toxicity (D.Brites 
et al., 2009; Fernandes and Brites, 2009) pointing to a mechanism that may represent the 
vulnerability evidenced by premature newborns (Bhutani and Johnson, 2006).  
 
2. SH-SY5Y cells exhibit greater sensitivity to UCB toxicity compared with other cells 
available in our laboratory and tested for UCB toxicity as neuronal progenitors from mouse 
striatal cells 2a1, primary culture of rat cortical astrocytes, HepG2 cells and HeLa cells. 
These results are in line with those reported by Ngai et al (Ngai et al., 2000). 
 
3. SH-SY5Y cells show a linear-progressive time dependent accumulation of intracellular 
radioactive [3H] UCB levels compared with other cell lines such as HeLa or 2a1 cells (data 
not shown). Such a rapid accumulation is relevant to the in vivo situation where UCB 
accumulates in brain tissues (Gazzin et al., 2012).  
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Based on this, we used SH-SY5Y cells to study the molecular events associated with bilirubin 
neurotoxicity. Firstly, we set our experiments by treating the SH-SY5Y cells in a time-dependent 
manner with a pro-oxidant concentration of UCB (140 nM Bf) that is clinically relevant and found 
in jaundice newborns. SH-SY5Y cells suffer a 40% loss of cell viability that occurred between 1h 
to 4h after UCB exposure, then cells reach a plateau till 24h (Results, Fig 9). This allowed us to 
study the molecular mechanisms of UCB toxicity while cells are suffering and at the same time 
the possible endogenous pathways that provide cell survival.  
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5.2 UCB mediates oxidative stress and cells respond by activation of multiple 
antioxidant genes, in part via Nrf2 
 
 
Nrf2 activation in response to oxidative stress mediated by UCB 
Recent studies suggest OS or changes of cellular redox state as a hallmark of UCB induced 
neurotoxicity. Our first goal was to study the effects of UCB on OS and how the cells response to 
overcome oxidative damage. We have previously demonstrated the involvement of OS in 
mediating cell death by UCB in SH-SY5Y cells after 24h of treatment, and reducing cell death by 
antioxidant NAC (Deganuto et al., 2010). In the present study, we observed an early increased of 
intracellular ROS level in SH-SY5Y cells after 1h of UCB treatment (Results, Fig 10).  
Cell response to OS mainly depends by cell type, the nature of toxic compound, and the 
outcome of signaling pathways. OS induces multiple cellular signal transduction (sensors) that 
determine cell fate. Cells may undergo cell cycle arrest until homeostasis is restored. When cells 
are unable to restore homeostasis they proceed to apoptosis, while cell survival depends on the 
ability of cells to restore homeostasis and resist the stress. This is why mammalian cells have 
developed redox sensitive proteins that aim to restore cellular redox state and provide cell survival 
(Martindale and Holbrook, 2002; Trachootham et al., 2008; Shackelford et al., 2000). Among all, 
Nrf2 pathway represents the primary response to OS and has attracted attention as a promising 
target to counteract neurological diseases due to its potent ability to up-regulate cytoprotective 
enzymes (de Vries et al., 2008; Calkins et al., 2009; Johnson et al., 2008). Based on this, we 
hypothesized that SH-SY5Y cells may undergo an adaptive response against OS through Nrf2 
pathway activation.  
Increased ROS level is associated with a rapid and early nuclear accumulation of Nrf2 proteins 
in SH-SY5Y cells upon UCB exposure (Results, Fig 12). To confirm whether the UCB-induced 
nuclear accumulation of Nrf2 is not restricted to SH-SY5Y cells, we repeat the same experiment 
in HepG2 cells. We choose this cell line, because hepatocytes represent a well-known model to 
study the molecular mechanisms of cell resistance to UCB toxicity, and can tolerate a UCB 
concentration three times higher than neuronal cells (Granato et al., 2003). HepG2 cells treated 
with UCB increased the nuclear accumulation of Nrf2 proteins (Results, Fig 13) and showed an 
up-regulation of HO-1 and NQO1 (Results, Fig 20), suggesting the activation of Nrf2 pathway in 
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HepG2 cells. A recent study demonstrated that UCB causes a nuclear translocation of Nrf2 
proteins in primary culture of mouse hepatocytes which was responsible for the inductions of 
bilirubin oxidation enzyme CYP2A5, and suggests Nrf2 activation as an additional mechanism in 
the adaptive response to UCB toxicity (Kim et al., 2013). The activation of Nrf2 pathway in 
hepatic derived cells is expected since many members of cytochrome P450 (CYPs) play a major 
role in bilirubin oxidation (Abu-Bakar et al., 2005; Kapitulnik and Gonzalez, 1993). CYPs 
catalytic activity is the major system for ROS generation (Zangar et al., 2004) that may directly 
activate Nrf2 pathway (Kohle and Bock, 2007). However, we observed a weakly or non-detectable 
mRNA expression of CYP1A1, CYP1A2, CYP2A6, CYP1B1, and CYP2D6 in SH-SY5Y cells 
(data not shown). Furthermore, mRNA expression of Aryl Hydrocarbon Receptor (AHR: the 
bilirubin binding transcription factor involved in CYPs induction (Ramadoss et al., 2005)) was 
not detected in SH-SY5Y cells (data not shown), suggesting a limited role for CYPs system in 
bilirubin oxidation (or ROS generation) in SH-SY5Y cells. 
UCB induces ARE and up-regulates multiple antioxidant enzymes 
Transcription factors face competition within the nucleus. To confirm whether the 
accumulated nuclear Nrf2 protein in SH-SY5Y cells is transcriptionally active toward ARE, we 
used a reporter gene composed of GFP under the control of ARE. GFP signal was increased in 
response to UCB exposure (Results, Fig 15) indicating that the accumulated nuclear Nrf2 protein 
was transcriptionally active toward ARE element. In line with this observation, we detected an 
up-regulation of several Nrf2 candidate genes upon UCB treatment. When we analyzed these 
genes in terms of time of response, they maybe divided into two main categories: early (4 h–8 h) 
and late response (16 h–24 h) (results, Table 4). As far as early genes, UCB mediated a sequential 
transcription starting with the ATF3 up-regulation at 4h and followed by the induction of amino 
acid transporters at 8 h (xCT and Gly1). On the contrary, for late genes, we observed an up-
regulation of the enzymes involved in GSH synthesis/homeostasis (γGCL and TRX1), 
antioxidant/detoxification (HO-1, NQO1, FTH) and NADPH homeostasis (ME1, and G6PD). 
These results indicated that the cells exposed to UCB aim to restore cellular redox state through 
the induction of several antioxidant response genes and that this response is time-related.  
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Following the genes expression pattern we observed that: (1) The induction of most of major 
antioxidant enzymes is occurred at late time suggesting that oxidative stress is a secondary event 
and the cells are dealing with another signaling pathways at early time (specially those involved 
in ATF3 induction and ER stress (see below section 5.3)). These results are similar to that 
observed in oligodendrocyte precursor cells treated with UCB where the induction of GRP78 at 
24h is suggested as a secondary effect of the ROS generation triggered by UCB, while ER stress 
appears to occurr very early (Barateiro et al., 2012). (2) The induction of antioxidant enzymes is 
specific for several genes except CAT, SOD, and GPx. This selectivity is dependent on cell type 
and nature of chemical inducer. (3) The PRDx2 was down-regulated at 24h upon UCB exposure. 
The signaling involved in this down-regulation is still unknown, however, the high antioxidant 
level at 24h (composed of GSH and HO-1/NQO1) may form a negative feedback for the 
expression of PRDx2.   
Nrf2 siRNA reduces the induction of only of HO-1, NQO1, and FTH 
To identify the genes up-regulated by UCB at Nrf2-dependent manner, we knockdown Nrf2 
mRNA expression. Nrf2 siRNA leads to reduced HO-1 and NOQ-1 induction  by  UCB  indicating  
that  Nrf2  is  involved  in  the  transcription of these genes upon UCB exposure (Fig 22). On the 
contrary, Nrf2 silencing did not affect the UCB-induced expression of ATF3, xCT, Gly1, γGCL, 
TRX1 and ME1, suggesting that other signaling are involved in the transcriptional regulation of 
these genes. 
FTH induction by UCB is also reduced by Nrf2 siRNA, however, it is possible that this 
reduction was due to the down-regulation of HO-1 rather than to the direct effect of Nrf2 siRNA, 
since FTH expression is usually coordinated with HO-1 expression (Vile and Tyrrell, 1993b). This 
also may indicate that HO-1 possess a significant catalytic activity that will generate biliverdin 
(reduced to bilirubin), which for a while seems surprising, since the cells were treated with 
bilirubin. Induction of HO-1 by UCB was observed in mouse hepatoma cell line (Oakes and Bend, 
2010), in HepG2 cells (Results, Fig 20) and primary culture of astrocytes (Results, Fig 30). There 
is no doubt that HO-1 induction is mainly due to OS in SH-SY5Y cells (Results, Fig 24) but 
several hypothesis may explain this up-regulation: (1) Bilirubin treatment forms a negative 
feedback to biliverdin reductase enzyme, thus HO-1 works toward biliverdin formation. This may 
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create a balance between bilirubin degradation and synthesis resulting in a redox buffer composed 
of bilirubin oxidation by ROS and biliverdin reduction by BVR (see introduction Fig 3). (2) HO-
1 may have another important role in reducing OS independent from its catalytic activity. Studies 
showed that the inactive form of HO-1 protein itself acts as an antioxidant, protecting cells from 
oxidative stress and increasing glutathione content (Lin et al., 2007; Hori et al., 2002). 
Nrf2 siRNA by itself is not sufficient to increase cell sensitivity to UCB toxicity 
When we tested the effects of Nrf2 silencing on the cell sensitivity to oxidative damage 
induced by UCB, Nrf2 siRNA did not sensitize cells to UCB toxic effects (Results, Fig 23), 
suggesting that other pathway(s) may compensate the loss of Nrf2. One possible candidate is the 
GSH. Previous studies demonstrated that resistance to GSH depletion involves Nrf2/HO-1 
activation (Furfaro et al., 2012), while increased levels of GSH reduced Nrf2/HO-1 activation 
(Min et al., 2011). These data suggest a cross talk between Nrf2/HO-1 and GSH cycle. We 
hypothesize that SH-SY5Y cells transfected with Nrf2 siRNA were still able to maintain redox 
state homeostasis through GSH enzymes upon UCB exposure. Supporting this hypothesis our 
previous results demonstrating that SH-SY5Y cells exposed to UCB show an increased level of 
intracellular GSH (Giraudi et al., 2011). In addition, the present data showed that the induction of 
genes involved in GSH homeostasis occurred at Nrf2-independent manner. When cells transfected 
with siRNA were incubated with BSO (a specific inhibitor for GSH synthesis), cells became more 
sensitive to UCB toxicity, pointing to the involvement of both Nrf2 and GSH in cellular redox 
homeostasis upon UCB exposure and suggesting Nrf2 pathway as a part of an adaptive response 
against UCB toxicity rather than to be the principle one.  
Oxidative stress and PKC are the major signaling involved in the activation of Nrf2/HO-1 axis 
Our results showed that HO-1 was highly induced by UCB (Results, Table 4) and its induction 
was mainly dependent on Nrf2 (Results, Fig 22A). This allowed us to identify the up-stream 
molecular mechanisms involved in Nrf2/HO-1 axis activation. HO-1 is a sensitive and fairly 
ubiquitous marker for OS (Keyse and Tyrrell, 1989; Ferrandiz and Devesa, 2008; Stefan W.Ryter, 
1997). Induction of HO-1 was occurred only when cells treated with toxic concentration of UCB 
(140 nM Bf), and this induction was reduced by (70%) in cells treated with antioxidant NAC (a 
glutathione precursor), indicating the involvement of OS in Nrf2/HO-1 activation (Results, Fig 
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24). Furthermore, HO-1 is widely accepted as a bona fide to detect the activated signalling 
pathways upon OS (Paine et al., 2010; Lee and Surh, 2005). However, cells type and nature of 
chemical inducer determine the specific activation of certain protein kinases (Pae et al., 2008; 
Martindale and Holbrook, 2002). For example, SH-SY5Y cells treated with H2O2 involves HO-1 
induction via PI3K and MEK1/2 pathways (Chien et al., 2011) while nitric oxide mediates 
Nrf2/HO-1 activation through PKC (Zhang et al., 2009). Limited information is available 
regarding the signalling pathways activated by UCB and their contribution in mediating neuronal 
cell survival or toxicity. The maximal reduction of HO-1 induction (80%) in SH-SY5Y cells 
treated with PKC inhibitor suggesting that this signalling is the main pathway involved in HO-1 
induction by UCB. The reduction of HO-1 induction by P38α (40%), and MEK-ERK1/2 (25%) 
inhibitors further indicated the activation of these signalling pathways by UCB and their partial 
contribution in HO-1 induction, while PI3K and JNK signalling appeared not to be involved in 
HO-1 induction by UCB (Results, Fig 24).  
Bilirubin an endogenous Nrf2 pathway inducer: Possible link to the indirect antioxidant therapy? 
UCB induced cytotoxicity is specific for certain types of neurons (e.g., Purkinjie) in brain, 
while other cell types (or organs) demonstrate high resistance to UCB toxicity (e.g., astrocytes 
and hepatocytes). This rise the question about the role of bilirubin in these organs. Cells that 
possess high resistance to UCB toxicity are suggested to benefit from “direct” antioxidant 
properties of bilirubin, based on the popular model of bilirubin-biliverdin redox cycle described 
by Baranano et al (Introduction, Fig 3). However, further investigations are needed to clarify 
direct antioxidant properties of bilirubin, since another study demonstrated a limited role for 
bilirubin-biliverdin redox cycle in the cellular antioxidant protection (Maghzal et al., 2009).  
Compounds that activate Nrf2 represent a novel therapeutic approach to overcome oxidative 
stress related disease (Jung and Kwak, 2010). In vivo, a novel strategy for reducing oxidative stress 
associated diseases (cardio vascular disease, cancer, and inflammatory syndromes) was suggested 
by increasing serum UCB level (McCarty, 2007). An inverse relation between elevated level of 
bilirubin and oxidative stress associated diseases was observed, especially in patients with Gilbert 
syndrome (characterized by mild hyperbilirbinemia) (Rigato et al., 2005; Vitek et al., 2006; Vitek 
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et al., 2002). However, these in vivo data are mainly indirect and the molecular mechanism of this 
cytoprectection is still not defined and based on the hypothesis of bilirubin-biliverdin redox cycle. 
Our data – in line with recent published study (Kim et al., 2013) – demonstrated Nrf2 pathway 
activation by hyperbilirubinemia suggesting that bilirubin is a potential endogenous “indirect 
antioxidant” compound that activate Nrf2 pathway. This may represent a positive response to the 
pro-oxidant concentration of UCB in the cells that are able to tolerate UCB toxicity, by activating 
cellular antioxidant system through Nrf2 and providing cell protection against OS. Indeed, in 
previous study we observed that SH-SY5Y cells pre-exposed to UCB (140 nM Bf) show a greater 
resistance to H2O2 compared to un-exposed cells (Giraudi et al., 2011). We suggest that the 
cytoprotection under elevated hyperbilirubinemia is related to Nrf2 pathway that provide cell 
protection against OS. According to that hypothesis, it will be interesting to study Nrf2 pathway 
activation in animals and subjects with hyperbilirubinemia. Further studies are need to confirm or 
confute this hypothesis. 
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5.3 UCB mediates ER stress as the earliest event and cell respond by activation of 
UPR 
 
 
UCB mediates sequential response of UPR sensors 
Oxidative stress and ER stress are two events linked together. From the present data, it is 
evident that ATF3 up-regulation at 4h represents the earliest response to UCB exposure (Results, 
Table 4), and occurred at Nrf2 independent manner (Results, Fig 22D). This gene is induced by 
several stimuli (Hai et al., 1999). However, the first signaling to consider is the ER stress, because 
ATF3 is suggested as a putative marker of UPR (Jiang et al., 2004). We extended this observation 
by analyzing the downstream signaling of UPR. ATF3 together with other ER stress biomarkers 
(ATF4 and CHOP) are induced in coordination with mechanisms requiring the phosphorylation 
of eIF2α by activated PERK (Oyadomari and Mori, 2004; Jiang et al., 2004). We previously 
demonstrated that activation of ER stress components is the main response mediated by UCB in 
SH-SY5Y cells (at 24h) but were unable to detect an early response (at 4h) by microarray approach 
(Calligaris et al., 2009). By the more sensitive qRT-PCR analysis we detected an up-regulation of 
ER stress biomarkers upon UCB exposure at 4h (PERK (Results, Table 5), CHOP and ATF4 
(Results, Fig 26), followed at 8h by XBP1, ATF6, and BiP (Results, Fig 27). These data suggest 
that ER stress (via PERK activation) represents one of the earliest response to UCB toxicity in 
SH-SY5Y cellular model. This is in agreement with published data that showed PERK/eIF2a 
activation (at 1h) associated with ATF3/CHOP induction (at 6h) after UCB treatment (Oakes and 
Bend, 2010). 
UCB mediates loss of cyclin D1 protein and cell cycle arrest 
UCB ability to arrest the cell cycle progression in vascular smooth muscle (Peyton et al., 2012) 
and tumour cells (Ollinger et al., 2007) has been demonstrated. Recent in vivo study by our group, 
showed that the cerebellum of UGT1A1 -/- Gunn rat exhibits an increase of cell cycle arrest, 
characterized by decrease of cyclin D1 protein (Robert et al., 2013). More importantly, we have 
previously observed that SH-SY5Y cells exposed to UCB showed a reduced progression of the 
cells through S-phase (Deganuto et al., 2010) and when released in medium after a 24h of UCB 
treatment, cells show a reduction in cell growth rate compared to DMSO treated cells (data not 
shown). Loss of cyclin D1 under ER stress present an important mechanism of checkpoint control 
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that prevent cell cycle progression until homeostasis is restored (Brewer et al., 1999). Because of 
the presence of ER stress (PERK activation that will leads to translation block) we suspected a 
modulation in cyclin D1 protein by UCB. Indeed, we detected a dramatic loss of cyclin D1 protein 
after 1h of UCB exposure in SH-SY5Y cells (Results, Fig 26D). However, loss of cyclin D1 
maybe mediated by the translation block evoked by GCN2 (Hamanaka et al., 2005) and/or mTOR 
signaling (Hashemolhosseini et al., 1998) discussed below.  
ATFs/CHOP/xCT/HO-1induction by UCB is not affected by PERK siRNA 
To test the possible involvement of PERK signaling in the induction of ATFs/CHOP/xCT by 
UCB we knockdown PERK mRNA. Surprisingly, PERK siRNA did not cause that major effects 
on the induction of ATFs, CHOP, and xCT by UCB (Results, Table 5). To discuss these results 
we can hypothesize two different scenario: (1) The trace amount (around 30%) of PERK 
remaining in cells after siRNA is sufficient to mediate eIF2α phosphorylation/ATFs-CHOP 
inductions, especially when cells are exposed to UCB because PERK mRNA is induced 4 fold 
(Results, Table 5). However, if PERK was the main signaling involved in UCB mediated 
ATF3/CHOP induction we should detect an effect on that genes induction. (2) The involvement 
of another signaling that may compensate PERK, This point will be discussed below.  
Since PERK activation leads to Nrf2 pathway activation under ER stress (Cullinan and Diehl, 
2004), we tested the effects of PERK siRNA on HO-1 induction. PERK siRNA does not reduced 
the induction of HO-1 by UCB suggesting the presence of another signalings that mediate HO-1 
induction. Another indirect logic scenario include calcium release under ER stress, generation of 
ROS (Malhotra and Kaufman, 2007), and/or activation of PKC/Nrf2/HO-1 pathway (Niture et al., 
2009). 
UCB induces GCN2 in PERK siRNA 
PERK and GCN2 are belong to the same family of kinases that are able to phosphorylate eIF2α 
and evoke the induction of ATFs/CHOP and amino acid transporters (Harding et al., 2003). 
Further studies demonstrated GCN2 to cooperate with PERK in the inhibition of translation via 
eIF2α phosphorylation under ER stress and amino acid deprivation (AAD) (Hamanaka et al., 
2005; Wang et al., 2013), suggesting a cross-talk between eIF2α kinases. In agreement with this, 
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we observed an up-regulation of GCN2 in cells transfected with PERK siRNA (not with control 
siRNA) upon UCB exposure for 4h (Results, Fig 29A), suggesting GCN2 induction to 
compensate the loss of PERK. The down-regulation of GCN2 after 16h by UCB in both control 
siRNA and PERK siRNA (Results, Fig 29B), suggest a negative loop that regulate GCN2 
expression, most probably due to the over-expression of multiple amino acid transporters (e.g., 
xCT and Gly1) and high level of cellular amino acids at that late time. Indeed, in the previous 
work we observed by microarray approach that 24h of UCB exposure induces many of amino acid 
transporters (Calligaris et al., 2009), suggesting the activation of amino acid response and GCN2 
pathway. 
Possible involvement of other signaling pathways 
AAD is known to affect another important signaling that is involved in the control of protein 
synthesis and translation called mTOR. This signaling is inactivated in response to several 
conditions include energy stress, AAD, glucose deprivation, oxidative stress, perturbation of Ca+2 
level …etc, (Laplante and Sabatini, 2012). Apparently, SH-SY5Y cells exposed to UCB are 
suffering from several conditions in a cascade of signaling. By our results we can hypothesize 
some of them: (1) The decrease of MTT test starting 1h after UCB exposure (Results, Fig 9) could 
indicate an energy stress related to mitochondrial dysfunction. (2) The up-regulation of 
glucose/charbohydrate uptake transporters after 24h of UCB exposure (Calligaris et al., 2009), 
suggests that cells had suffered from glucose deprivation at early time, a condition that resulting 
in un-proper protein glycosylation in ER and thus activate UPR. (3) Amino acid synthesis is 
depend on the intermediates of glycolysis and krebs cycle, suggesting that the presence of glucose 
deprivation and/or energy stress – if any – will influence the amino acid synthesis in SH-
SY5Ycells exposed to UCB. (4) Furthermore, the presence of ER stress suggesting the impairment 
of Ca+2 signaling, indicated by PKC activation.  
mTOR inactivation results in translation inhibition and several studies demonstrated the up-
regulation of CHOP/ATFs independent from GCN2 (AAD) or eIF2α signaling (ER stress) 
(Entingh et al., 2001; Bunpo et al., 2009; Thomas et al., 2008), pointing out the potential risk using 
CHOP/ATFs as unique marker for ER stress. Even we didn’t study mTOR signaling we 
hypothesize that mTOR play an important role in the induction of CHOP/ATFs by UCB. More 
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experiments are needed to evaluate the link of these signaling (UPR/GCN2/mTOR) (Hamanaka 
et al., 2005) upon UCB exposure.  
Furthermore, mTOR inactivation is tightly linked to the activation of autophagy (Codogno 
and Meijer, 2005). Most evidence implicates autophagy as a mechanism to restore cellular 
homeostatic and recover from stress through the removal of damaged proteins and organelles by 
the lysosome. However, excessive autophagy can lead to cell death. In addition, ER stress 
induction can stimulate autophagy (Benbrook and Long, 2012). Indeed, we observed that UCB 
(at 24h) mediates induction of many genes involved in autophagy in SH-SY5Y cells (Calligaris 
et al., 2009).  
It is worth to keep in mind the characteristics of the in vitro model that we used 
(neuroblastoma), and the possible involvement of the previous signaling in cancer-cell adaptation 
to UCB mediated stress signals. An ideal experiment need to be performed in the primary culture 
of neurons from different brain regions and astrocytes. Comparative studies will identify the 
selectivity of UCB induced neurotoxicity, and which of the previous signaling(s) are involved. 
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5.4 Proposed model of UCB activates divers signaling in SH-SY5Y cells  
 
 
 
Figure 32: Proposed model of UCB mediated OS and activation of antioxidant response in SH-SY5Y 
cells. UCB mediated OS enhances the nuclear accumulation of Nrf2 and induction of ARE. UCB induces 
expression of several antioxidant-response genes. Among all, HO-1 and NQO1 are Nrf2 dependent 
(highlighted with gray box) while others (highlighted with blue box color) are involved by another 
transcriptional machinery (most probably, through ER stress transcription factors). Nrf2/HO-1 activation 
by UCB involved OS and PKC. Activation of UPR sensor by UCB represents an early event as 
demonstrated by the up-regulation of PERK, ATFs/CHOP, XPB1 and ATF6. GCN2 and mTOR signaling 
could be also involved in ATFs/CHOP induction by UCB. 
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5.5 Astrocytes, a model of resistance, up-regulates antioxidant genes, not ER stress.  
Toward understanding the selective toxicity  
 
 
Astrocytes displayed a greater resistance to UCB toxicity than neurons (Brito et al., 2008b). 
We decided to analyze the expression of some genes involved in divers signaling including HO-
1, NQO1, ATF3, CHOP, and xCT upon UCB exposure (140 nM Bf) to Cx astrocytes. 
 
HO-1 and NQO1 (marker for Nrf2 activation) were induced by UCB exposure, while xCT 
was not induced (Results, Fig 30), suggesting the activation of Nrf2 pathway. However, this 
induction is weak compared with the SH-SY5Y cells and this is maybe related to the abundant 
and effective basal expression of ARE-responsive genes in astrocytes compared to neurons (Shih 
et al., 2003). Indeed, the basal expression of HO-1 and NQO1 was very high in Cx astrocytes 
compared to SH-SY5Y cells (data not shown). This could be one of the explanation why astrocytes 
are less sensitive to oxidative damage upon UCB exposure. Based on this, the first hypothesis to 
explain selective toxicity of bilirubin induced injury would be based on the threshold 
concentrations between the anti- and pro-apoptotic effects of the pigment, which mainly depends 
on cell type, basal expression of antioxidant enzymes, and the ability to activate Nrf2 pathway. 
 
ATF3 and CHOP (markers of ER stress) expression was not changed by UCB exposure while 
induced by DTT (Results, Fig 31), suggesting that UCB does not induce UPR (or another 
signaling such as GCN2/mTOR) in Cx astrocytes. Only three studies (one in neuroblastoma cell 
line (Calligaris et al., 2009), one in oligodendrocites (Barateiro et al., 2012), and one in hepatoma 
(Oakes and Bend, 2010)) demonstrated ER stress activation by UCB, suggesting a selective 
activation of UPR by UCB. The selectivity of UCB induced ER stress toward specific cell types 
in brain is still completely unknown. Recent study about Huntington’s disease, showed ER stress 
activation by protein aggregates that affects striatal cells compared with non-striatal cell types as 
relevant to in vivo conditions, suggesting for a selectivity of ER stress outcome in different cell 
types (Leitman et al., 2013). Based on this, the second hypothesis to explain selective toxicity of 
bilirubin induced injury would be based on the threshold level of UPR activation among different 
cell types. 
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6. CONCLUSION AND PERSPECTIVES 
 
 
Although bilirubin encephalopathy was described more than 200 years ago and it is still a 
major clinical concern for pediatrics, the molecular mechanism of UCB induced neurotoxicity is 
incompletely elucidated. This study is just a little contribution toward understanding UCB induced 
neurotoxicity. Because free bilirubin (Bf) is the main determinants of UCB pathological 
properties, we took advantage from our experience in the measurement of Bf. Our studies were 
performed with Bf concentration that is clinically relevant in neonatal jaundice. 
In the present work we tried to discover the early molecular mechanisms involved in UCB 
induced neurotoxicity using the neuroblastoma cell line SH-SY5Y, regularly used as an in vitro 
model for neurotoxicity. UCB induced neurotoxicity is a multifaceted process, however, a 
growing body of evidences suggest OS and ER stress as important mediators of UCB toxicity. We 
focused our first attention on the studies related to redox biology, in particular, the effects of UCB 
on Nrf2 pathway, a master cellular sensor for cellular redox state that has never been reported in 
studies related to UCB induced neurotoxicity. We observed that UCB increased ROS level, 
associated with an early nuclear accumulation of Nrf2 protein and induction of ARE reporter gene. 
In line with this, cells up-regulate multi-antioxidant genes upon UCB exposure, some of them 
(HO-1 and NQO1) were Nrf2 dependent and others (xCT, Gly1, γGCL, TRX1, ME1, and ATF3) 
were not. Regarding the up-stream mechanisms, we detected OS and PKC as the major signaling 
involved in Nrf2/HO-1 activation upon UCB exposure. All these data indicated the activation of 
antioxidant response as a fundamental system to reduce UCB mediated OS and Nrf2 activation as 
part of that adaptive response. More experiments should be performed in the future, in order to 
clarify the direct role – if any – for Nrf2 pathway in cell protection against UCB toxicity using  
Nrf2 -/- mouse and eventually cross-breeded with UGT1A1 -/- mouse. If the role of Nrf2 will be 
confirmed, Nrf2 activators (antioxidants) should be considered as a possible candidate for 
therapeutic treatment to overcome bilirubin encephalopathy.  
Results that we obtained suggest ER stress as another important player in UCB toxicity. UCB 
mediates activation of UPR response (via PERK signaling) associated with ATFs/CHOP 
inductions as one of the earliest response to UCB toxicity, indicating the importance of this 
signaling in the outcome of UCB induced neurotoxicity. siRNA against PERK dose not changed 
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ATFs/CHOP induction  suggesting the involvement of another signaling in ATFs/CHOP 
induction or a compensatory mechanism which is indicated by GCN2 induction upon UCB 
exposure.  
This work is the first demonstration of bilirubin induced Nrf2 pathway activation in neuronal 
cell line. We believe the data relevant to the understanding of the neurotoxicity of bilirubin, which 
is present in some of the newborns immediately after birth. 
Scientists involved in bilirubin neurological damage, in cell signaling response to oxidative 
stress and in antioxidant therapies could be interested in this study. Though I have come a long 
way during 3 years of PhD the remaining path is certainly longer. 
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